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1.1 Pain  
The ability to sense the world is essential for adequate response to environmental stimuli, 
which determines survival of the organism and, consequently, drives evolution. Different 
sensory modalities enable the detection of specific stimuli, with the traditionally recognized 
five senses, also known as sound, sight, touch, smell, and taste, operating continuously and 
oftentimes even “unperceived” to decode any input and therefore direct essentially any 
response and action. Among them, the most primitive and indeed the most essential to 
survival is the sense of touch, better referred to as somatosensation. The somatosensory 
system is complex and encompasses different submodalities, namely:  
 Touch: detection of mechanical stimulation of the body; 
 Proprioception: detection of mechanical displacement of muscles and joints; it 
contributes to sense the position of the body and limbs; 
 Thermosensation: detection of a wide range of temperatures, from cold to heat; 
 Nociception: detection of noxious (painful) stimuli, of mechanical, thermal and 
chemical nature; 
Nociception is probably the most enigmatic of these submodalities, mainly because of the 
dual nature that is associated to pain. On the one hand in fact, pain has, as the other 
submodalities, a fundamental physiological role, as it is protective against stimuli that have 
the potential to harm the body, and triggers protective and defensive mechanisms aimed at 
ceasing the threatening condition. Because this pain is involved with the sensing of noxious 
stimuli, it is referred to as nociceptive or acute pain, a high-threshold pain only activated in 
response to stimuli intense enough to potentially create damage (Basbaum et al., 2009; 
Woolf, 2010). The paramount importance of acute pain is exemplified in people born with 
congenital insensitivity to pain, which is caused by rare mutations in the genes coding for the 
voltage-gated sodium channels Nav1.7 (Cox et al., 2006), Nav1.9 (Leipold et al., 2013) or 
neurotrophin receptor TrkA (Indo et al., 1996). These individuals experience harmful 
conditions without any protective reaction, undergoing bone fractures, self-mutilations, 
amputations, and often die early in life as a result of injuries. The importance of acute pain is 
also revealed in cases of peripheral neuropathy, where sensory denervation of joints leads to 
severe damage and deformities due to lack of pain sensitivity (Haus et al., 2010; Mabilleau 
and Edmonds, 2010).  
 
On the other hand however, pain is also the first reason that people seek medical attention. 
Pain can extend beyond its protective usefulness, becoming pathological and chronic. In this 
case, pain is maladaptive and is believed to result from abnormal functioning of the nervous 
system, becoming a disease state in its own right (Costigan et al., 2009).  In Europe, chronic 
pain of moderate to severe intensity is estimated to affect almost 20% of the adult 
population, which results in serious damage to the quality of the patients‘ social and working 
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life, in addition to a huge economic burden (Breivik et al., 2006). Effective treatment of many 
chronic pathological pain conditions has not been achieved so far and faces major 
challenges. Current pain therapeutics are either not effective in some clinical settings, or 
they are too often characterized by extremely narrow safety windows and intolerable side 
effects. In the light of these difficulties, it is of primary importance finding new therapeutic 
targets for the development of novel, more effective, and better-targeted analgesics. A 
special focus is needed in order to identify ways to interfere selectively with the pathological 
side of pain, while preserving the physiological function of acute pain, and therefore an 




1.2 Nociception and the pain pathway 
In order to figure out how to potentially target pain, we need to understand how the 
sensation of pain is generated. In 1986, the International Association for the Study of Pain 
(IASP) defined pain as “a sensory and emotional experience associated with actual or 
potential tissue damage, or described in terms of such damage” (Merskey, 1994). Pain is a 
complex experience made up of sensory, affective, motivational and cognitive dimensions, 
which is physiologically associated, but different from, nociception. Nociception refers to the 
neurophysiological consequences induced by a noxious stimulation, and starts with the 
detection of such stimulus through specialized primary afferent neurons which innervate 
both the skin and internal organs, the so-called nociceptors.  
 
The term nociceptor was coined in the early 1906 by Sir Charles Scott Sherrington, whose 
pioneering studies led him to the conclusion that the skin is provided with a set of nerve 
endings with the specific function of sensing potentially harmful stimuli (Sherrington, 1903). 
Sherrington’s “specificity theory” was contrasting the then widely believed notions that pain 
was caused by a central summation upon excessive sensory stimulation, and that nerve 
endings were all alike (Woolf and Ma, 2007). The nociceptor is nowadays widely recognized 
for its specific function in triggering the nociceptive process, and extensive knowledge has 
been developed about the different properties and specific characteristics that mark distinct 
populations. Nociceptors, like other primary somatosensory neurons, show a 
pseudounipolar morphology, with their cell bodies located in dorsal root ganglia (DRG, for 
most of the trunk and limbs innervation), trigeminal ganglia (TG, for cephalic innervation), 
jugular ganglia and nodose ganglia (vagal innervation of head and viscera)(Kollarik et al., 
2010). They possess a single process that originates from the cell body and bifurcates into a 
peripheral axon that innervates the target tissue, and a central axon that synapses on 
second-order neurons in the dorsal horn of the spinal cord (for DRG neurons) or in the 
trigeminal subnucleus caudalis (for TG neurons)(Basbaum et al., 2009; Dubin and 
Patapoutian, 2010). Nociceptive neurons are rather heterogeneous and can be classified 
based on different properties, for instance the diameter of the axon, which correlates well 
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with the speed of transmission of action potentials and whether the fiber is myelinated. This 
aspect is also reflected in the specific qualities of pain signaled. The initial fast-onset pain, 
usually perceived as burning, pricking and well-localized, is mediated by medium-diameter 
Aδ-fiber nociceptors, whose axons are thinly myelinated with conduction velocities of 
approximately 5–30 m/s (Djouhri and Lawson, 2004). Most nociceptors, however, have small 
diameter non-myelinated axons, called C-fibers (Woolf and Ma, 2007) with conduction 
velocities of 0.4–1.4m/s (Djouhri and Lawson, 2004). They signal a slower-onset pain, with 
throbbing, burning and poorly localized qualities.  
 
Nociceptors are unique in their ability to sense noxious stimuli of physical and chemical 
nature, which is possible because they express specific receptors and ion channels that are 
the real primary detectors of the noxious stimulus. The range of stimuli they respond to is 
also a direct reflection of the specific receptors they express. Such molecular transducers act 
in free nerve endings to encode the noxious stimulus into a signal that is then transmitted to 
the somata of the neurons (in DRGs or TGs) and eventually conveyed to second-order 
neurons and local interneurons in the dorsal horn of the spinal cord (Fig.1). Here, different 
fibers terminate in anatomically and electrophysiologically distinct laminae (Basbaum and 
Jessell, 2000). Specifically, Aδ nociceptors project to lamina I as well as to the deeper lamina 
V, whereas C-fiber nociceptors synapse more superficially mainly to laminae I and II (Snider 
and McMahon, 1998). Projection neurons within laminae I and V constitute the main output 
from the dorsal horn to higher order systems, travelling through five major ascending 
pathways: the spinothalamic, spinoreticular, spinomesencephalic (or spinoparabrachial), 
cervicothalamic, and spinohypothalamic tracts (Basbaum and Jessell, 2000). These 
nociceptive pathways convey the information to different cervical structures, with the 
different nuclei of the thalamus representing the principal relay structures of sensory 
information. The lateral and medial nuclear thalamic groups are involved in the reception, 
integration, and transfer of the signal primarily to the somatosensory cortices and other 
cortical structures (Basbaum and Jessell, 2000).  The insula receives impulses from several 
pathways and its projections are directed at the limbic system, mainly amygdala and some 
areas of the prefrontal cortex (PFC). The anterior cingulate cortex (ACC) coordinates inputs 
from parietal areas with frontal cortical regions that integrate the perception of bodily 
threats and contributes to the response priorities of pain behavior (Almeida et al., 2004).  
 
In general, there does not seem to be a single brain region essential for pain perception 
(Apkarian et al., 2005). Instead, pain seems to be the result of complex activation of a wide 
number of structures, some of which contribute to the sensory-discriminative components 
(as the somatosensory cortex) while others are more associated with the affective-
emotional aspects (such as the insula, the anterior cingulate cortex and the limbic system) 
(Basbaum and Jessell, 2000). These structures work in an orchestrated way in the 
deconvolution of the sensory stimulation, but also in its modulation, which then affects pain 
response. Several mechanisms of descending pain regulation have been discovered, among 
which a serotonergic and a monoaminergic systems which originate in the periaqueductal 
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grey matter and the locus ceruleus (and other medullar nuclei), respectively. But the best 
known is definitely the endogenous opioid system: opioid peptides and their receptors are 
widely distributed throughout the body and constituted the major target of exogenous pain 
suppression from the ancient Sumerians in 3300 BC to our times (Basbaum and Jessell, 
2000). Clearly such a strategy of targeting widely expressed molecules involved in several 
functions is inevitably linked to a cascade of side-effects, to which we can add a dangerous 
addictive potential (Ueda and Ueda, 2009).  
 
A seemingly more reasonable strategy to target pain is to target cellular processes and 
mechanisms that are as much as possible specific for pain, so that interfering with such 
mechanisms would ideally spare other physiological functions from unwanted 
consequences. From looking at the different steps in the pain pathway, the nociceptor 
clearly stands out for its unique ability in sensing the noxious stimulus and triggering the 
nociceptive process, and is therefore a desirable target where to find mechanisms that are 
as much as possible nociception-specific. 
 
 
Figure 1. The pain pathway.  
Noxious stimuli of physical and chemical nature are detected by primary afferent nociceptors, which encode 
them into a signal that is transmitted first to their somata and then to second-order neurons in the dorsal horn 
of the spinal cord. DRGs harbor the cell bodies of these neurons, many of which are small diameter non-
10 
 
myelinated C-fibers, with low conduction velocities. Thinly-myelinated afferents correspond to faster-signaling 
Aδ nociceptors, while big-diameter myelinated neurons mainly convey touch and proprioception signals. In the 
spinal cord, the sensory information is integrated locally and then conveyed to higher-order circuitry in the 




1.3 The nociceptor in chronic pathological pain 
A great number of cases of chronic pain are associated with altered excitability and activity 
of primary afferent neurons, potentially caused by pathological processes that follow 
inflammation (inflammatory pain) or nerve injury (neuropathic pain). The etiology of such 
processes can be diverse, including physical trauma, metabolic disease, infections and 
chemotherapy. (Sousa-Valente et al., 2014). Made for distinguishing innocuous from noxious 
stimuli, nociceptors exhibit a high threshold of activation. However, in response to injury and 
inflammation the nociceptors’ activation characteristics can be modulated in a process 
known as peripheral sensitization, which represents a form of functional plasticity of the 
nociceptor (Woolf and Ma, 2007). Basically, at the site of inflammation/injury a variety of 
signaling molecules and cellular mediators are released as a result of disruption of cells, 
infiltration and activation of immune cells and induction of enzymes, which together make 
up an “inflammatory soup” that acts on primary afferent neurons to modify their response 
properties. Cytokines, chemokines, growth factors, prostaglandins, proteases, all contribute 
to changes in the chemical milieu of the nociceptor resulting in a reduced threshold of 
activation and increased responsiveness to stimuli. These phenomena translate respectively 
into allodynia (response to innocuous stimuli) and hyperalgesia (exaggerated pain response 
to noxious activation), which are thought to contribute to the etiology of clinically relevant 
chronic pain syndromes (Patapoutian et al., 2009). As a consequence, activity-dependent 
changes in the spinal cord lead to increased neurotransmitter release and enhanced 
excitability of second-order sensory neurons which may promote central sensitization (Ji et 
al., 2003).   
 
The wide variety of sensitizing agents acting in parallel in this process makes potential 
blockage of their effects a rather poor option for the reduction of pain (analgesia). 
Nonetheless, blockage of prostaglandin synthesis by inhibition of cyclooxygenase (COX) 
enzymes has been the basis of most non-steroidal anti-inflammatory drugs (NSAIDs). Whilst 
non-selective inhibition of COX produces a significant analgesic effect, they are molecules 
widely expressed in the body and therefore, their clinical use is limited by serious side 
effects (Kidd and Urban, 2001). Many other pharmacological agents designed to achieve 
analgesia by either decreasing neuronal excitation or increasing inhibition suffer from the 
same issues and a strategy targeting molecules and their molecular scaffolds, which are 
selectively expressed or highly enriched in the primary detectors of noxious stimuli is highly 
desirable. As already mentioned, the nociceptor houses specialized receptors and ion 
channels that endow it with the unique ability to sense physical and chemical stimuli and 
11 
 
translate them into a signal that will then be propagated along the pain neuraxis and 
culminate into pain perception. These molecules are the real primary detectors of the 
noxious stimulus and are highly enriched in nociceptive neurons (Basbaum et al., 2009). In 
fact, to date many of these receptors and ion channels have become important targets in 
the search for new pain therapies (Wood et al., 2004) and the biggest advances in 
understanding their identity and function were certainly led by the discovery of Transient 
Receptor Potential (TRP) ion channels as the largest superfamily of sensors for temperature 




1.4 Transient receptor potential (TRP) ion channels 
1.4.1 General information 
TRP channels are present in a large variety of multicellular organisms, and the mammalian 
TRP channel superfamily encompasses 28 members, which are subdivided into 6 subfamilies 
based on their sequence homology: TRPA (ankyrin), TRPC (canonical), TRPM (melastatin), 
TRPML (mucolipin), TRPP (polycystin) and TRPV (vanilloid) (Benemei et al., 2015). A more 
distant TRPN group (also known as no mechanoreceptor potential C or NOMPC) has not 
been found in mammals, but is expressed in flies, worms and cold-blooded vertebrates 
(Moiseenkova-Bell and Wensel, 2011; Montell, 2001). In addition, even yeasts and other 
fungi have been reported to express a TRP channel subfamily known TRPY (yeast) 
(Moiseenkova-Bell and Wensel, 2011). TRP proteins share a common structure, which 
consists of six putative transmembrane domains (TM) with a pore-forming loop (P) between 
the fifth (S5) and sixth segments (S6) (Nilius et al., 2007). The N- and C-termini are both 
intracellular and seem to contribute to the regulation of channel assembly and function. 
Functional TRP channels are constituted of four pore-forming subunits that have been 
shown to potentially assemble as both homo-tetramers and hetero-tetramers (Benemei et 
al., 2015; Zheng, 2013). Several specific properties have been used to differentiate and 
classify TRP subfamilies, among which the number of ankyrin repeats, coiled-coil regions and 
TRP signature motifs. TRP proteins form ion channels that are mostly non-selective for 
monovalent and divalent cations, but several exceptions have been reported such as TRPM4 
and TRPM5, which show a great selectivity for monovalent cations, and TRPV5 and TRPV6 
that are instead highly selective for Ca2+ ions (Smani et al., 2015).  
 
To date, much evidence has accumulated demonstrating an important role of TRP channels 
in cellular processes in both a physiological and pathophysiological context. They function as 
ligand-gated, second messenger-operated or receptor-operated channels coupling such 
events to the transmembrane flow of ions down their electrochemical gradients. The influx 
of Na+ and Ca2+ ions inside the cell may in turn contribute to membrane depolarization and 
the activation of Ca2+-dependent pathways in a variety of systems and organs (Clapham, 
2003). In excitable cells, variations in transmembrane potential determine in fact action 
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potential generation and muscle contraction (Ramsey et al., 2006). Furthermore, 
dysregulation of TRP channel activity and function, which might be linked to abnormal 
expression levels, impaired trafficking or mutations, has been associated with a large 
number of disorders, thus revealing the crucial biological relevance of these channels (Smani 




1.4.2 Role in sensory transduction 
Many TRP channels are peculiar in their functional properties that allow them to function as 
cellular sensors (Clapham, 2003). The first clue that they could be involved in sensory 
transduction emerged from the first identification of a TRP ion channel in Drosophila 
melanogaster (Montell and Rubin, 1989).  It was observed that a fly mutant displayed a 
transient instead of sustained response to stimulation with bright light, hence the name of 
the protein family. Among different organisms, TRP channels show disparate functions, 
which are partially shared among closely related species. For instance, yeasts use a TRP 
channel to perceive and respond to hypertonicity (Zhou et al., 2003). Nematodes like C. 
elegans instead possess TRP channels in their ‘noses’ at the tips of neuronal dendrites where 
they are needed for detection and avoidance of noxious chemicals (de Bono et al., 2002). In 
mammals TRP channels have demonstrated a clear role as major players in chemesthesis, 
osmoregulation and thermosensation.  
 
Thermosensation is a fascinating chapter which advances have been precipitated by the 
identification of seven highly temperature-sensitive ion channels (the so-called thermoTRPs) 
as candidate temperature sensors. They are expressed in sensory nerve endings and in the 
skin, where they couple activation by distinct thermal ranges to transmembrane ion flow 
(Ferrandiz-Huertas et al., 2014). So far, five heat-activated channels (TRPV1-4 and TRPM3) 
and two cold-activated channels (TRPM8 and TRPA1) have been reported to contribute to 
mammalian thermosensation, even though the debate is still open (Dhaka et al., 2006; 
Ferrandiz-Huertas et al., 2014; Patapoutian et al., 2003). All seven, when expressed in 
heterologous expression systems (like HEK293 cells or Xenopus oocytes), showed the 
amazing property of making the cells temperature-sensitive within their specific activation 
window. Each thermoTRP has in fact unique characteristics, as indicated by different 
thresholds of activation, which combined cover the whole spectrum of temperature 
sensation in mammals (Fig.2). While the precise molecular determinants of temperature 
detection are still unknown, the identification of structural elements in these channels 
indicates an important role of the intracellular N- and C- termini in determining the 
temperature range of activation (Bandell et al., 2007). The ability to sense internal and 
environmental temperatures thanks to these channels are fundamental not only for 
maintenance of homeostasis, but also for avoidance of harmful noxious temperatures. 




Several TRP channels (among which most of the thermoTRPs) have also shown a clear role in 
chemesthesis, here referred to as the chemical sensitivity of the skin and membranes to 
endogenous and exogenous molecules and that is perceived as pungency, irritation, cooling, 
warmth, or heat. Examples of chemesthesis include the irritating effects of concentrated 
saline solutions on the nasal mucosa, or painful sensations evoked by inhaling vehicle 
exhaust gas. Other examples are the irritation and pain caused by eating hot chili peppers, 
due to the active ingredient capsaicin, which is known to directly activate the TRPV1 channel 





Figure 2. Thermosensitive transient receptor potential channels (thermoTRPs).  
Several members of the TRP channels superfamily showed to mediate temperature sensation by coupling 
activation by temperature to flow of ions through the membrane. They all share a common topology with six 
transmembrane domains (S1–S6) and a pore loop between S5 and S6. N- and C-termini are intracellular and 
four subunits associate into functional channels. ThermoTRPs show distinct thermal activation ranges from 
noxious cold (TRPA1) to potentially harmful heat (TRPV1 and TRPV2). Most thermoTRPs showed also a role in 
chemesthesis, sensing a variety of natural chemicals known to induce the respective thermal sensations in 







1.4.3 TRP channels and pain 
The superfamily of TRP channels constitutes the largest group of molecular sensory 
transducers so far known to be involved in pain signaling in mammals, with ten members 
(TRPV1to4, TRPA1, TRPM2-3-8, TRPC1-6) that showed a clear role in nociceptive processing, 
as listed in table 1. 
 
TRP channel References 
TRPV1 (Caterina et al., 2000; Caterina et al., 1997)  
TRPV2 (Caterina et al., 1999; Nagy and Rang, 1999) 
TRPV3 (Peier et al., 2002b; Smith et al., 2002) 
TRPV4 (Alessandri-Haber et al., 2003; Liedtke et al., 2000) 
TRPA1 (Obata et al., 2005; Story et al., 2003) 
TRPM2 (Haraguchi et al., 2012; Kudoh et al., 1997) 
TRPM3 (Lee et al., 2003; Vriens et al., 2011) 
TRPM8 (Bautista et al., 2007; Knowlton et al., 2010) 
TRPC1 (Alessandri-Haber et al., 2009; Zitt et al., 1996) 
TRPC6 (Alessandri-Haber et al., 2009; Boulay et al., 1997) 
 
Table 1. Transient receptor potential (TRP) ion channels known to be involved in mammalian nociception. 
 
Among these channels, some of them as TRPV1, TRPM8 and TRPA1 have drawn special 
attention because they have been shown to be highly expressed in nociceptors, where they 
play major roles as transducers of noxious stimuli and modulators of nociceptive signaling. 
Activation of these channels is involved in acute pain signaling and furthermore their 
regulation and sensitization significantly contribute to pathological pain conditions (Sousa-





In the elucidation of the molecular mechanisms of noxious temperature sensation, limited 
progress was made until 1997, when the TRPV1 channel was cloned by the Julius’ lab 
(Caterina et al., 1997). TRPV1 is a member of the vanilloid subfamily of TRP channels that 
showed a clear enrichment in nociceptive neurons, and reported properties of a noxious 
heat–activated channel with a thermal activation threshold close to 43°C (Caterina et al., 
1997; Julius, 2013). TRPV1 is also responsible for the irritation and pain caused by hot chili 
peppers, due to the active ingredient capsaicin, which is a direct and specific agonist. Indeed 
TRPV1-deficient (knock out) mice showed partial deficits in the detection of acute thermal 
stimuli, which confirms a role for this channel in heat-evoked pain, and complete 
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abolishment of capsaicin-induced pain responses (Caterina et al., 2000; Caterina et al., 
1997). In addition to heat and natural compounds, TRPV1 can be activated and modulated 
by lipids, voltage and phosphorylation (Pingle et al., 2007).  
 
Importantly, many cellular mediators produced in the context of tissue injury and 
inflammation (components of the mentioned inflammatory soup) can dramatically affect 
TRPV1 function, reducing its threshold of activation and, as a result, increase nociceptor 
excitability. TRPV1 is therefore a fundamental component of the cellular mechanisms that 
lead to peripheral sensitization and, consequently, drive the clinically relevant 
manifestations of pain hypersensitivity (hyperalgesia and allodynia) (Basbaum et al., 2009; 
Caterina et al., 2000; Davis et al., 2000). TRPV1-deficient mice indeed showed attenuated 
thermal hyperalgesia induced by inflammatory molecules such as bradykinin and nerve 
growth factor (NGF) (Caterina et al., 2000; Chuang et al., 2001; Davis et al., 2000).  In 
addition, injection of oleoylethanolamide, an endogenous TRPV1 agonist, induces 
nocifensive (pain-related) behavior in mice that is absent in TRPV1-deficient animals and can 
be blocked by the TRPV1 antagonist capsazepine (Wang et al., 2005).  Modulation of TRPV1 
has therefore clear potential for pain therapy and pharmacological blockade or knock-down 
of TRPV1 displayed analgesic activity in different animal pain models (Chu et al., 2011; Szabo 
et al., 2005). In 2010 capsaicin patches (Qutenza®) have been approved in the USA for the 
treatment of post-herpetic neuralgia and a recent study involving a total of over 2000 
participants claimed that high-concentration capsaicin patches could be effective even for 
the treatment of HIV-induced neuropathy (Derry et al., 2013). However, since TRPV1 
inhibition lowers the sensitivity to noxious heat, this might lead to an increased susceptibility 
to injury and it has been associated to a risk of increased body temperature (hyperthermia) 





TRPM8 has been shown to respond to a variety of natural and synthetic cooling agents, such 
as menthol, eucalyptol and icilin, as well as to cold stimuli, with an activation temperature 
proximal to 26°C (Dhaka et al., 2006). TRPM8 shares TRPV1 topology, forming a 
homotetrameric nonselective cation channel permeable to calcium ions (McCoy et al., 2011; 
Peier et al., 2002a). In sensory neurons TRPM8 is enriched in a subpopulation of primary 
afferents which, interestingly, does not overlap the neuronal subset which instead expresses 
TRPV1 and TRPA1, suggesting the existence of “labelled lines” in sensory transduction and 
signaling. (Almaraz et al., 2014). TRPM8-deficient mice exhibited profound deficits in their 
ability to discriminate between cold and warm surfaces, or to respond to evaporative 
cooling, demonstrating the essential role of TRPM8 in thermosensation (Bautista et al., 
2007). Furthermore, injury-evoked cold hypersensitivity is impaired in animal models of both 
inflammatory and neuropathic pain, advancing the prospect that therapeutic modulation of 
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TRPM8 may provide relief to patients who suffer from altered sensitivity to cold (Colburn et 
al., 2007). TRPM8 antagonism showed analgesic potential in a rat model of neuropathic pain 
(Calvo et al., 2012; Parks et al., 2011) and has been associated with a reduction of cold 
hypersensitivity following tissue injury (Knowlton et al., 2010). Nonetheless, to date no 
TRPM8 modulator has advanced to clinical trials. 
 




1.5 TRPA1  
1.5.1 Gene and protein structure 
TRPA1 was for the first time identified in 1999 by Jaquemar and colleagues and originally 
baptized ANKTM1 by the Patapoutian lab as it contains multiple ankyrin repeats in the N-
terminal part (Jaquemar et al., 1999; Story et al., 2003).  The Trpa1 gene is well conserved 
and several TRPA1 homologues have been discovered in the animal kingdom. In addition to 
mammals, it is present in many vertebrates and invertebrates, including rodents, flies and 
worms. However, in contrast to mammals that contain only one Trpa1 gene, many other 
classes from the animal kingdom express different TRPA1 homologues (Nilius et al., 2012). 
TRPA1 is a protein of about 1,100 aminoacids (120–130 kDa), with only one splice variant 
identified in mouse (Zhou et al., 2013). TRPA1 shows a topology similar to the other TRP 
channels, with six transmembrane domains and a pore loop between S5 and S6 and 
cytoplasmic N- and C- termini (Fig.3). The peculiarity of TRPA1 is an exceptionally long region 
within the N-terminus containing 14-18 ankyrin repeat domains (ARs), which could be 
involved in protein–protein interactions and channel trafficking to the plasma membrane 
(Nilius and Flockerzi, 2014). Deletions of TRPA1 ARs have been shown, in fact, to negatively 
affect the insertion of the channel into the plasma membrane (Nilius et al., 2011). The N-
terminal region contains also several important cysteine residues, which can interact and 
form disulfide bridges within and between monomers (Cvetkov et al., 2011). In its functional 
configuration, four TRPA1 subunits associate into tetramers, usually homo-tetramers. 
(Nassini et al., 2014). Recently, the Julius’ lab determined a ~4 Å resolution of TRPA1 
obtained by Cryo-electron microscopy, which furnished important structural insights, as well 
as shedding some lights on potential regulatory mechanisms, much needed for the design of 
selective channel modulators (Paulsen et al., 2015). Like most family members, TRPA1 is a 
non-selective cation channel with an inward depolarizing current mainly due to Na+ and Ca2+ 








Mammalian TRPA1 is a promiscuous channel that can be activated by a plethora of 
endogenous mediators and natural compounds. Environmental chemicals that target TRPA1 
include allyl isothiocyanate, better known as mustard oil (MO), cinnamaldehyde, and allicin, 
which are the pungent active ingredients that characterize mustard seeds, cinnamon, and 
garlic, respectively. Many airborne irritants also directly activate TRPA1, among them heavy 
metals and isocyanates produced during industrial manufacturing (Bautista et al., 2013). 
Another TRPA1 agonist is acrolein, that in addition to be found in tear gas, cigarette smoke 
and vehicle exhaust gas, it can be formed endogenously under conditions of inflammation 
(Bautista et al., 2006).  
 
TRPA1 is targeted also by a wide number of endogenous metabolites and inflammatory 
molecules. One example is reactive oxygen species (ROS), which levels dramatically increase 
in response to tissue damage and can initiate lipid peroxidation (Bautista et al., 2013).  These 
processes lead to the formation of different reactive carbonyl species, among which 4-
oxononenal (4-ONE) and 4-hydroxynonenal (4-HNE), which in turn target TRPA1 directly 
(Taylor-Clark et al., 2008a; Trevisani et al., 2007). Another characteristic of inflammatory 
states is the formation of reactive nitrogen species (RNS). Among RNS, nitric oxide (NO) is 
the most potent TRPA1 activator and it is an important component of the mechanisms that 
underlie pain sensitization upon inflammation and injury (Nilius et al., 2012). At sites of 
injury and inflammation COX enzymes mediate the production of a variety of prostaglandins, 
which mediate inflammatory responses. One prostaglandin D2 derivative, 15d-PGJ2, 
specifically activates TRPA1 expressed in HEK cells as well as in mouse sensory neurons 
(Cruz-Orengo et al., 2008; Taylor-Clark et al., 2008b). Interestingly, also some commonly 
used anesthetics, both general (as isoflurane) and local (as lidocaine), are able to activate 
TRPA1 (Leffler et al., 2011; Matta et al., 2008).  
 
Several studies indicated for TRPA1 a gating model involving both voltage-dependent 
activation and inactivation of TRPA1, with the pore helix playing an essential role in the 
process (Samad, 2011; Wan et al., 2014). TRPA1 activation is coupled to influx of calcium 
(among other ions) into the cells, which itself has been shown to modulate the channel. 
Calcium plays two opposing roles in regulating TRPA1 activity. TRPA1 currents in response to 
pungent chemicals like mustard oil are rapidly potentiated and subsequently inactivated in 
the presence of extracellular calcium (Doerner et al., 2007; Wang et al., 2008b; Zurborg et 
al., 2007). On the other hand, TRPA1 activity can be blocked by intracellular calcium 
(Akopian et al., 2007; Nagata et al., 2005; Wang et al., 2008b; Zurborg et al., 2007) Several 
reports showed that TRPA1 contributes to acute cold responses (Karashima et al., 2009; 
Kwan et al., 2006; Story et al., 2003) even though its role as an acute cold sensor has not 
been always confirmed (Caspani and Heppenstall, 2009). A recent report demonstrated that 
human TRPA1 expressed in artificial membranes is intrinsically cold sensitive and supports 
18 
 








Figure 3. A schematic view of TRPA1 structure and activation modalities.  
Two TRPA1 subunits are shown, although the channel is comprised of four. Each subunit contains six 
transmembrane domains (S1-S6) with a pore helix between S5 and S6. Ankyrin repeats (AR) characterize the N-
terminal region, and a coiled-coil structure the C-terminus. TRPA1 is targeted by a variety of endogenous 
molecules with pro-inflammatory properties, environmental irritants, a plethora of natural compounds and 
potentially noxious cold. Channel activation is coupled to pore opening and transmembrane calcium flow. 












TRPA1 is localized to both neuronal and non-neuronal tissues as the inner ear, skin and 
pancreas. Among them, TRPA1 shows a high enrichment in sensory neurons of dorsal root 
ganglia (DRG), trigeminal ganglia (TG), and nodose ganglia, where it functions as a major 
player in nociception (Nilius et al., 2012). In DRGs, TRPA1 is expressed in unmyelinated (C-
fiber) and thinly-myelinated (Aδ) primary afferents, with only occasional identification in 
large myelinated axons. More than 25 % of TRPA1 containing neurons are peptidergic and 
release Substance P and Calcitonin gene-related peptide (CGRP), while the remaining 
neurons were identified as non-peptidergic neurons by immunoreactivity with the plant 
lectin Isolectin B4 (IB4; ~45 %). The dorsal horn of the spinal cord and trigeminal sensory 
nuclei are immunoreactive for TRPA1, indicating the location of nociceptive synapses into 
second-order neurons (Nilius et al., 2012). In sensory neurons, TRPA1 is also usually 
coexpressed with TRPV1 channels, in Peripherin-positive small diameter neurons of DRGs 
and TGs (Kobayashi et al., 2005; Story et al., 2003). In fact, ablation of TRPV1 neurons with 
resiniferatoxin (a superpotent TRPV1 agonist) in mice results in loss of response to both 
capsaicin and mustard oil (Pecze et al., 2009), suggesting a high degree of colocalization of 




1.5.4 Role in pain 
There is now widespread agreement that TRPA1 plays an important role as a primary 
detector of noxious stimuli, by sensing a wide variety of exogenous and endogenous 
molecules with pro-inflammatory and pro-algesic properties. (Andrade et al., 2012; Bautista 
et al., 2013). The creation of TRPA1-deficient animals and the development of specific 
antagonists have confirmed TRPA1 as a major player in acute and inflammatory pain. Several 
studies in TRPA1-deficient mice identified clear behavioral deficits in response to mustard 
oil, formaldehyde and profound deficiencies in some models of inflammatory hyperalgesia 
and airway irritation (Bautista et al., 2006; Kwan et al., 2006). TRPA1 has been implicated in 
the development and maintenance of hypersensitivity in a number of animal pain models. In 
models of inflammatory pain, rodents treated with TRPA1 antagonists or TRPA1-deficient 
animals have displayed a clear attenuation of mechanical hyperalgesia evoked by injection of 
tumor necrosis factor α (TNFα), Complete Freund’s Adjuvant (CFA), or monoiodoacetate 
(Fernandes et al., 2011; Laing and Dhaka, 2015; McGaraughty et al., 2010). To further claim 
the importance of TRPA1 in pain signaling, gain of function mutations in the gene coding for 
TRPA1 have been associated with the only human channelopathy with pain phenotype so far 
linked to the TRP superfamily. This rare disease, called familial episodic pain syndrome 
(FEPS), is characterized by bouts of excruciating pain especially in the upper body, triggered 
by mild stress and cold temperatures (Kremeyer et al., 2010). It is now well established that 
TRPA1 contributes to the pathophysiology of headache by dural mechanisms. TRPA1 on 
meningeal nerve endings is involved in headache episodes induced by exposure to 
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environmental irritants, but is has also a potential role in migraine. TRPA1 is expressed in a 
population of dural primary neurons and activation of meningeal TRPA1 produces behaviors 
that recapitulate those observed in migraine attacks (Edelmayer et al., 2012; Nassini et al., 
2014). While a clear-cut role for TRPA1 in acute noxious cold sensation cannot be 
unambiguously demonstrated yet, several studies have demonstrated TRPA1 contributions 
to the state of hypersensitivity to cold temperature (cold allodynia) that occurs in the 
settings of tissue and nerve injury. TRPA1 antagonism specifically reduced cold 
hypersensitivity in rodent models of inflammatory and neuropathic pain (del Camino et al., 
2010; Karashima et al., 2009). TRPA1 is also critically involved in pain induced by anticancer 
treatment with platinum-based compounds, as cisplatin and oxaliplatin, which oftentimes 
lead to cold and mechanical hypersensitivity (Nassini et al., 2011). Antimitotic drugs, such as 
paclitaxel, are also known to induce peripheral neuropathy. Application of paclitaxel has 
been shown to stimulate ROS formation that in turn potentiates TRPA1 activation. These 
effects could be prevented by TRPA1 inhibition with specific antagonists (Materazzi et al., 
2012). Furthermore, TRPA1 antagonism has proved effective in attenuating the mechanical 
allodynia and cutaneous nerve fiber loss in a rat model of streptozotocin-induced diabetes 
(Koivisto et al., 2012). 
 
Together, these findings advocate a role for TRPA1 in the mechanisms underlying peripheral 
neuropathy, and in general support TRPA1 as an interesting therapeutic target for 
pharmacological intervention aimed at quelling pain. Inhibition of TRPA1 with HC-030031, a 
specific TRPA1 antagonist, effectively inhibited formalin-induced pain (McNamara et al., 
2007) and displayed analgesic potential in a rat model of neuropathic pain (Eid et al., 2008). 
Several companies have showed interest in TRPA1 and reported diverse selective 
antagonists, among them Abbott, Merck and Janssen. Abbott for instance developed a 
molecule named A-967079, which inhibited spontaneous and mechanically evoked firing of 
neurons in uninjured, inflamed, and osteoarthritic rats (McGaraughty et al., 2010), in 
preclinical studies. However, as for TRPV1, direct inhibition of channel function would result 
in deficits also in acute pain sensation that is undesirable and asks for better-targeted 





Beyond direct activation by its ligands, TRPA1 function can be sensitized or modulated via 
mechanisms implicated in phenomena of hypersensitivity, which in turn contribute to 
clinically-relevant chronic pain conditions (Hucho and Levine, 2007; Patapoutian et al., 
2009). Modulators are diverse and include the inflammatory mediators mentioned above, 
lipid metabolites and intracellular signaling pathways (Hucho and Levine, 2007). Among 
them, it has been reported that NGF participates in the functional up-regulation of TRPA1 in 
sensory neurons (Diogenes et al., 2007) and that bradykinin and proteinase-activated 
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receptor 2 (PAR2) can sensitize TRPA1 via phosphorylation and via activation of PLC, which in 
turn releases TRPA1 from phosphatidylinositol-4,5-bisphosphate (PIP2)-mediated inhibition 
(Chen et al., 2011; Dai et al., 2007; Wang et al., 2008a). A recent study reported on the 
modulation of TRPA1  by the extracellular miRNA let7-b which, via functional coupling to the 
toll-like receptor-7 (TLR7), induced direct activation and excitation of nociceptive sensory 
neurons to evoke pain (Park et al., 2014).  
 
In addition, the abundance of TRPA1 channels at the plasma membrane of sensory neurons 
has been identified as a crucial contributor to TRPA1 signaling; in this line the induction of 
TRPA1 membrane trafficking has been described upon activation of the channel by MO, or 
PKA/PLC signaling, which might contribute to the sensitization of TRPA1-mediated 
nocifensive behaviors of mice upon acute activation and inflammatory signals, respectively 
(Schmidt et al., 2009). TRPA1 membrane abundance is also affected by the coexpression 
with TRPV1, which seems to counteract pharmacological desensitization of TRPA1 by 
preventing channel internalization (Akopian et al., 2007; Ruparel et al., 2008).  Recently, a 
TRPA1 splice isoform named TRPA1b has been identified and showed to colocalize, interact 
and furthermore increase the expression of TRPA1 channels to the plasma membrane and, 
consequently, affect mouse pain behavior (Zhou et al., 2013).  
 
These studies highlight the impact the regulation of TRPA1 channels can exert on neuronal 
activity. In general, comprehensive knowledge on the mechanisms of TRPA1 regulation is still 
missing, especially about the potentially relevant contribution of the whole network of 




1.6 Protein complexes as modulators of receptor function in pain 
Among the mechanisms of regulation of ion channels and receptors, a special focus is due to 
the major contribution of protein-protein interactions. Diverse cellular processes and 
molecular mechanisms are brought about by the concerted organization of dynamic 
interactions among proteins, which crucially modulates the properties of the single binding 
partners. Assembly into multi-protein complexes has indeed been shown also for different 
ion channels in the pain pathway, and it has been linked to modifications of intrinsic 
channels properties (e.g. open-probability, activation threshold, (in)activation kinetics), 
trafficking, expression and post-translational modifications (Rouwette et al., 2015). These 
events then translate in altered neuronal excitability as well as facilitation and inhibition of 
synaptic transmission, which ultimately contribute to modulate pain perception and 
response in both physiological and pathophysiological contexts (Costigan et al., 2009; Gold 
et al. 2006). For example, membrane trafficking, synaptic targeting and degradation of 
AMPA-type glutamate receptors are regulated by a network of protein interactions, which 
ultimately effects synaptic plasticity (Anggono and Huganir, 2012; Schwenk et al., 2012). In 
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analogy, protein complexes associated with NMDA-type glutamate receptors are critically 
involved in the pathophysiology of chronic inflammatory pain (Tappe et al., 2006), and 
targeting such interactions showed therapeutic potential (Liu et al., 2008). In this context it is 
worth mentioning the interaction of GASP1 with type 1 cannabinoid receptor (CB1), which 
mediates cannabinoid-induced internalization and exposes a molecular basis of analgesic 
tolerance to cannabinoids (Tappe-Theodor et al., 2007). These studies advocate a major 
contribution of protein-protein interactions to the function of key players in nociceptive 
singaling, which ultimately contributes to determine pain response.   
 
Among TRP channels involved in nociception, much relevant literature is now available 
about dozens of protein complexes associated with TRPV1. Many of these interactors have 
been reported to modulate TRPV1 activity, and interfering with the binding proved in some 
cases to effectively attenuate hypersensitivity in animal pain models (Fischer et al., 2013; 
Kim et al., 2008). The most recent work from Hanack and colleagues on the complex 
between TRPV1 and the GABAB1 receptor subunit suggested that modulating the interaction 
has the impressive potential to selectively revert the sensitized state of TRPV1 channels 
implicated in pathological pain, while preserving TRPV1 acute pain signaling (Hanack et al., 
2015).  
 
In the case of TRPA1 however, much less is known about the network of associated protein 
complexes. Curiously, the still most relevant physical and functional interaction reported is 
with TRPV1, which largely coexpresses with TRPA1 in sensory neurons. (Salas et al., 2009; 
Staruschenko et al., 2010). The functional properties of the two channels are mutually 
modulated by the association (Akopian et al., 2007) and, on top of that, they have also been 
reported to form heteromers (Fischer et al., 2014). Very recently, a transmembrane adaptor 
protein called Tmem100 has been described to bind both TRPA1 and TRPV1 channels in 
sensory neurons. Mechanistically, Tmem100 seems to weaken their association and 
selectively potentiate TRPA1 activity; strikingly, a Tmem100 mutant showed the opposite 
effect, inhibiting TRPA1 response and attenuating both inflammatory pain and 
chemotherapy-induced neuropathy (Weng et al., 2015). In addition to TRPV1, TRPA1 has 
been reported to bind the PKA anchor protein AKAP5 and the human tumor suppressor CYLD 
(Stokes et al., 2006; Zhang et al., 2008). The latter is a ubiquitin hydrolase that seems to 
control TRPA1 cellular levels by a potential post-translational mechanism (Stokes et al., 
2006). In conclusion, it is indeed surprising that up to date only little is known about TRPA1-
associated protein complexes, and the lack of knowledge in this respect represents a clear 







1.7 Aims of the study 
A thorough understanding of the mechanisms underlying nociception is paramount to 
interpret the maladaptive changes that characterize chronic and pathological pain states. 
Much evidence now advocates TRPA1 as a major player in noxious stimuli transduction and 
pain signaling in vertebrates. Being highly enriched in nociceptors, where they serve as 
primary sensors to integrate polymodal stimuli and trigger nociceptive signaling, TRPA1 
channels represent ideal targets for developing new therapeutic strategies for pain 
conditions. While relevant literature is already available about TRPA1 activation modalities, 
still very little has been reported about the regulation of this channel, which ultimately 
affects its activity and function in both physiological and pathophysiological contexts. While 
several mechanisms have been proposed to affect protein function, the molecular network 
of protein interactions regulating TRPA1 (the so-called TRPA1 interactome) is only poorly 
understood.  
 
This study was therefore aimed at shedding some lights on the mechanisms of TRPA1 
regulation, with a special focus on identifying and characterizing novel TRPA1-protein 
complexes, as potentially crucial modulators of TRPA1 function and nociceptive signaling. 
The valuable knowledge we obtained contributes not only to a better understanding of 
TRPA1 channels in more detail, but also to nociceptive signaling in general; ultimately, this 
study might even contribute to reveal novel therapeutic targets for specific TRPA1-related 

























10X PBS (Phosphate-buffered saline) pH 7.4 Life Technologies 
10X HBSS (Hank’s balanced salt solution) Life Technologies 
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Goat serum Dianova 
BSA (bovine serum albumin) Sigma-Aldrich 
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2.1 Annexin A2 (AnxA2) regulates TRPA1-dependent nociception 
The gross part of the text relative to this section is based on (Avenali et al., 2014).  
 
2.1.1 Protein identification by mass spectrometry analysis and database search 
Proteins were identified by MS using an LTQ-Orbitrap mass spectrometer (Thermo Fisher 
Scientific) essentially as described previously (Gomez-Varela et al., 2012) except that tandem 
MS data were used to search a mouse-specific database with an appended reverse sequence 
copy (EBI-IPI database version 3.32). Proteins were only considered if they were identified by 
two or more peptides in both independent TRPA1 affinity purifications from trigeminal 
ganglia (TG) lysates and were absent in the two independent replicates of the control 
experiment (IgG). Scaffold (version Scaffold_4.0.5; Proteome Software) was used to validate 
MS/MS-based peptide and protein identifications. Peptide identifications were accepted if 
they could be established at >95% probability by the Peptide Prophet algorithm (Keller et al., 
2002). Protein identifications were accepted if they could be established at >95% probability 
and contained at least two identified peptides. The mass spectrometry-based identification 
and data analysis were performed before the start of my PhD project by the Genomics 




2.1.2 Cloning of the AnxA2 N-term deletion construct (ΔAnxA2) 
The cDNA of mouse AnxA2 was used as a template for a PCR designed to delete the first 15 
aa of the N terminus of AnxA2 using the following primers: GATCATTCTACACCCCCAAG and 
TCAGTCATCCCCACCACACAG. Primers were designed with BamHI and EcoRV restriction sites 
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to insert the PCR product into pcDNA3-PV-IRES-EGFP (a kind gift from Nils Brose, Max Planck 
Institute of Experimental Medicine, Göttingen, Germany). PCR reactions were performed 
using 150 ng template DNA, in 1X Pfx reaction buffer (Life Technologies), 300 µM dNTP mix 
(Thermo Scientific), 0.3 µM of each specific primer, 1 mM MgSO4 (Invitrogen), 1 U of 
Platinum Pfx DNA polymerase (Life Technologies). The thermocycler (Bio-Rad T100) was 
programmed as indicated: an initial denaturation step of 3 minutes at 94 °C, followed by 25 
cycles of amplification including  94 °C for 15 s, 55 °C for 30 s, 68 °C for 70 s, and at the end 
68 °C for 10 minutes. After the PCR reaction, the products were visualized using agarose gel 
electrophoresis, product bands excised and DNA purified using NucleoSpin gel and PCR 
clean-up kit (Macherey-Nagel) following manufacturer’s instructions. Digestion of vector and 
insert was performed by incubation with FastDigest restriction enzymes EcoRV and BamHI 
(Thermo Scientific) in 1X green buffer (Thermo Scientific) for 35 minutes at 37 °C. In order to 
prevent self-ligation, the vector was then dephosphorylated by treatment with FastAP 
thermosensitive alkaline phosphatase (Thermo Scientific) for 35 minutes at 37 °C. 
Immediately after the end of the incubation, samples were run on agarose gel to stop the 
alkaline phosphatase reaction and visualize the products. Bands were then excised and 
products purified again using NucleoSpin gel and PCR clean-up kit (Macherey-Nagel) 
following manufacturer’s instructions. For ligation, insert and vector (molar ratio 3:1) were 
mixed with 1 U of T4 DNA ligase (Life Technologies) in 1X ligase buffer (Life Technologies) for 
2 h at 25 °C. Subcloning efficiency DH5α E. coli competent cells (Life Technologies) were used 
for bacterial transformation. A mix of 50 µl cells and 5 µl ligated DNA product was incubated 
for 30 minutes on ice, then heat-shock transformation was performed by incubation at 42 °C 
for 25 s in a water bath, followed by 2 minutes on ice. Immediately after, 950 µl SOC 
medium (Invitrogen) were added, and the cells incubated at 37 °C for 1 h with shaking at 250 
rpm. Cells were then centrifuged at 6000 rpm for 1 minute, the pellet resuspended in 200 µl 
SOC medium and finally plated on LB agar (Roth) plates containing 100 μg/ml ampicillin 
(Roth). Plates were incubated at 37 °C overnight with shaking at 250 rpm. From the LB agar 
plate, 6 single colonies were picked and cultured in 5 ml of LB medium containing 100 μg/ml 
ampicillin. After overnight incubation at 37 °C with shaking at 250 rpm, 1 ml of the culture 
was used for plasmid purification using PureLink quick plasmid miniprep kit (Macherey-
Nagel) following manufacturer’s instruction. Amount and purity of the eluted DNA were 




2.1.3 HEK293T cell culture and transfection  
HEK293T cells were maintained at 37 °C, 5% CO2 in DMEM+GlutaMAX containing 10% FBS 
and penicillin/streptomycin. Upon transient transfection using FuGENE HD (Promega) 
following manufacturer’s instructions, cells were plated on coverslips (for calcium imaging 
and electrophysiology) or MatTek dishes (for live labeling) coated with poly-D-lysine (1 
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mg/ml) and laminin (20 µg/ml). Twenty-four hours after plating cells were used for 




2.1.4 Protein affinity purification from tissue lysates and coimmunoprecipitation 
from cell lysates 
HEK293T cells were transfected with cDNA encoding for mouse TRPA1-myc, AnxA2, ΔAnxA2, 
p11, TRPV1, or empty plasmid (Mock) and were plated in 10 cm cell culture dishes. After 24 
h cells were collected in PBS, centrifuged, and the cell pellet was resuspended in lysis buffer 
(150 mM NaCl, 50 mM Tris-HCl, pH 7.5, 0.5 mM EDTA, 10% glycerol, 1% NP-40, 0.5% sodium 
deoxycholate, complete protease inhibitor cocktail). TG were freshly extracted from male 
wild-type mice (6–12 weeks old), and homogenized in lysis buffer using a glass dounce 
homogenizer. After centrifugation (10,000 rpm, 10 minutes) the resulting supernatant from 
TG lysates was incubated at 4 °C for 5 h with 20 µg of TRPA1 antibodies (rabbit, E1 or E3; 
(Schmidt et al., 2009)) or 20 µg of rabbit IgG coupled to magnetic beads (Protein G 
Dynabeads; Life Technologies). The supernatant from HEK293T cell lysates was incubated at 
4 °C overnight either with 20 µg of myc antibody (9E11 mouse; Santa Cruz Biotechnology), 
10 µg of TRPA1 antibody (Schmidt et al., 2009), or with 20 µg of TRPV1 antibody (goat; Santa 
Cruz Biotechnology) coupled to magnetic beads. After five washes in lysis buffer, beads were 
eluted by incubation for 10 minutes at 70 °C in 40 µl of elution buffer containing the 
following: 1X lithium dodecyl sulfate sample buffer (Life Technologies) and 1X NuPAGE 
sample-reducing agent (Life Technologies). The resulting mixtures were resolved by 1D 
NuPAGE using the MES running buffer (Life Technologies). In case of tissue samples each 
resolved lane was cut into 16 equal gel slices, which were analyzed separately by mass 





2.1.5 Western blotting 
Protein gels of cell lysates were blotted on nitrocellulose or PVDF membranes using the iBlot 
System (Life Technologies) and afterwards blocked for 30 minutes in 5% milk powder in PBS. 
Membranes were then incubated overnight at 4 °C with primary antibodies to myc (9E11 
mouse; 1:100; Santa Cruz Biotechnology), Annexin A2 (rabbit; 1:100; Abcam), p11 (goat; 
1:40; R&D Systems), and TRPV1 (goat; 1:100; Santa Cruz Biotechnology) in 1% milk powder 
in PBS. After 3 washes in PBS, membranes were incubated for 2 h at room temperature with 
proper secondary antibodies anti-mouse Alexa680 (donkey; 1:8000; Life Technologies), anti-
rabbit Alexa680 (donkey; 1:8000; Life Technologies), anti-goat Alexa680 (donkey; 1:8000; 
Life Technologies) or anti-rabbit IR Dye 800 (donkey; 1:8000; Li-Cor). After 3 additional 
washes, detection of immunolabeled protein was performed using infrared imaging 
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(Odyssey; Li-Cor). Western blots were independently repeated three times. Only for 
presentation purposes were size, brightness, and contrast levels of paired blots (i.e., 





2.1.6 Dissociated mouse dorsal root ganglion neuron culture  
Dorsal root ganglia (DRG) were isolated from all spinal levels of 6-10 weeks old, male WT 
C57BL/6J mice. The mice were euthanized by CO2 inhalation followed by decapitation 
according to guidelines stated in the German Animal Welfare Act. The skin covering the 
spinal cord was removed and the spinal column with its adjacent connective tissue dissected 
out. The vertebral arches were sequentially removed to expose the spinal cord. The dorsal 
root ganglia were then carefully extracted from each of the intervertebral foramina. The 
tissue was first collected in serum free medium (DMEM/F12+GlutaMAX) then transferred 
into a falcon tube with 12 mg/ml collagenase. After 1 h of incubation at 37 °C, the tissue was 
triturated with a P1000 pipette. The DRGs were further dissociated via incubation with 10 
U/ml papain for 30 minutes at 37 °C. The DRGs were then centrifuged (1000 rpm; 1 minute) 
following which the supernatant was removed and the mix triturated again in serum-free 
media. To remove cell debris, a column of 0.15 g/ml BSA was added to the cell suspension 
and centrifuged (1000 rpm; 10 minutes). After the centrifugation, cell debris, media and BSA 
layer were removed carefully with a Pasteur pipette. For WT DRG cultures, cells were 
directly plated on 1 mg/ml poly-D-lysine and 20 μg/ml laminin-coated coverslips following 
resuspension in growth medium (DMEM/F12+GlutaMAX supplemented with 10% horse 
serum and growth factor mix containing: 100 ng/ml NGF, 50 ng/ml GDNF, 50 ng/ml BDNF, 50 
ng/ml NT-3, and 50 ng/ml NT-4).  After 10 minutes incubation of the cell suspension drop at 





2.1.7 Nucleofection of DRG cultures 
Transfection of neurons was achieved by nucleofection of cDNA into freshly isolated DRG 
neurons using the P3 Primary Cell 4D Nucleofector X Kit with the 4D-Nucleofector X Unit 
according to the manufacturer’s instructions (Lonza AG). (1) For calcium imaging rescue 
experiments 0.8 µg of mAnxA2-pCMVSport6 or empty pCMVSport6 were used, each in 
combination with 0.2 µg of pmaxGFP (Lonza AG), which was to visualize transfected neurons. 
(2) For live labeling 0.8 µg of mTRPA1-IRES-YFP was used and for rescue experiments an 
additional 1 µg of mAnxA2-pCMVSport6 or empty pCMVSport6 was used. (3) For 
electrophysiology 0.5 µg of mTRPA1-IRES-YFP was used. After nucleofection, neurons were 
allowed to recover in RPMI medium for 10 minutes at 37 °C before plating in growth 
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medium. Two hours after transfection half of the growth medium was exchanged with fresh 





Whole-cell voltage-clamp recordings were performed in transfected HEK293T cells or 
transfected DRG cultures at room temperature with standard patch pipettes (3–5 MΩ 
resistance) made of borosilicate glass capillaries. Current signals were recorded with an EPC-
9 patch-clamp amplifier (HEKA). Stimulus delivery and data acquisition were performed 
using Pulse software (HEKA). Current–voltage (I/V) curves were performed using voltage 
steps of 400 ms duration ranging from -100 to +175 mV followed by an invariant pulse at -75 
mV (400 ms). The holding potential was set to 0 mV. To repress inactivation of voltage-
dependent currents (Macpherson et al., 2007; Meseguer et al., 2014), these recording were 
made in Ca2+-free solutions [intracellular solution (in mM): 140 NaCl, 5 CsCl, 10 EGTA, and 10 
HEPES, pH 7.4, adjusted with NaOH; bath solution (in mM): 140 NaCl, 3 KCl, 1.3 MgCl2, 10 
HEPES, 1 EGTA, and 10 glucose]. Mustard oil (MO)-dependent currents in both TRPA1-
transfected HEK293T cells and TRPA1-transfected DRG neurons were recorded using an 
extracellular Ca2+-containing solution to preserve and study agonist desensitization 
properties (Macpherson et al., 2007); intracellular solution (in mM): 135 KCl, 2 MgCl2, 2 
MgATP, 5 EGTA, and 10 HEPES, pH 7.4; bath solution (in mM): 127 NaCl, 3 KCl, 1 MgCl2, 10 
HEPES, 2.5 CaCl2, and 10 glucose, pH 7.3]. The effect of MO on I/V curves was studied using 
voltage ramps of 500 ms ranging from -100 to +100 mV, applied every 5 s. The holding 
potential was set at -70 mV. Data analysis and representation were done using FitMaster 
(HEKA) and Igor Pro (WaveMetrics), respectively. Electrophysiology recordings were 




2.1.9 Ratiometric calcium imaging 
Ratiometric calcium imaging was performed essentially as described previously (Coste et al., 
2010) using an inverted microscope (Zeiss Axio Observer Z1). Briefly, cells were washed 
three times with calcium imaging buffer consisting of 1×HBSS (1.3 mM Ca2+) supplemented 
with 10 mM HEPES. A working solution of the ratiometric Ca2+ indicator dye Fura-2 was 
prepared resuspending 50 µg of Fura-2 AM cell permeant (Life Technologies) in 50 µl DMSO 
and adding additional 50 µl Pluronic F-127 (Life Technologies) and then diluting the mix 
1:200 in imaging buffer. Cells were incubated with the dye for 30-60 minutes at 37 °C, 
according to the manufacturer´s recommendations. Cells were then washed again three 
times prior to imaging. Fura-2 fluorescence was measured by illuminating the cells with an 
alternating 340/380 nm excitation light. Fluorescence intensity was measured at 510 nm for 
both excitation wavelengths and the intracellular Ca2+ concentration expressed as the 
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A340/A380 ratio. All experiments were conducted at room temperature 24-48 h after plating. 
For experiments testing cellular response to MO upon AnxA2 overexpression, HEK293T cells 
were stimulated with 0.1 μM/1 μM/10 μM/30 μM/100 μM MO for 2 minutes, followed by 2 
minutes of washout and final stimulation with 100 μM ATP to control for cellular health. For 
experiments testing response of DRG cultures from both genotypes, neurons were 
stimulated with the following protocol: 2.5 minutes with 12 μM MO; 5 minutes washout; 2 
minutes 50 μM MO; 5 minutes washout; 1.5 minutes 0.5 μM Capsaicin. For experiments 
assessing the pharmacological desensitization of TRPA1, the following stimulus protocol was 
applied: (1) application of 50µM MO for 2 minutes followed by a second 2 minutes 
application of 50 µM MO 2 minutes later (homologous desensitization) and (2) application of 
0.5 µM Capsaicin for 1.5 minutes followed by 2 minutes application of 50 µM MO 5 minutes 
later (heterologous desensitization; the longer interval between stimuli was necessary for 
recovery of intracellular calcium levels after Cap application). For data analysis, threshold for 
activation was set at 20% above the baseline obtained from averaging five time points 
immediately before addition of each stimulus. All experimental groups to be compared were 
processed in parallel using the same culture preparation. At least two coverslips from three 





Mice (ages 6–12 weeks) and rats (ages 6–8 weeks) were killed with CO2. DRG were carefully 
dissected, collected in 4% PFA/PBS, and fixed overnight at 4 °C. After cryoprotection in 30% 
sucrose/PBS overnight tissues were frozen in optimal cutting temperature compound, 
sectioned as step serial sections with a cryostat at 10 µm width, mounted on SuperFrost Plus 
slides, and stored at -80 °C. Frozen slides were thawed at room temperature for 30 minutes, 
washed three times in PBS with 0.4% Triton X-100 (PBT), blocked for 30 minutes in PBT 
containing 5% goat or donkey serum, and incubated overnight at 4 °C with primary 
antibodies diluted in blocking solution. The following antibodies were used: 1:50 rabbit anti-
TRPA1, custom-made E1 or E3 (Schmidt et al., 2009), or 1:100 rabbit anti-TRPA1 (Aviva 
Systems Biology); 1:100 rabbit anti-TRPV1 (Alomone Labs); 1:100 rabbit anti-Annexin A2 
(Abcam); 1:40 goat anti-p11 (R&D Systems); 1:100 chicken anti-Peripherin (Abcam); and 
1:200 rabbit anti-NF200 (Sigma-Aldrich). The antibody used on rat sections was 1:50 mouse 
anti-Annexin A2 (BD Biosciences). The sections were then washed five times in PBS and 
incubated for 2 h at room temperature with secondary antibodies conjugated to Alexa Fluor 
488, Alexa Fluor 546 or Alexa Fluor 647 (Life Technologies) diluted 1:250 in blocking solution. 







2.1.11 Image acquisition and analysis of immunohistochemistry 
Digital images of stained cryosections were obtained by fluorescence microscopy (either 
using a Zeiss Axio Observer Z1 epifluorescence microscope or the Leica SP5 confocal laser 
scanning microscope). Images for all experimental groups were taken using identical 
acquisition parameters. All groups to be compared were processed simultaneously using the 
same culture or tissue preparation. Raw images were analyzed by using NIH ImageJ 
essentially as described previously (Schmidt et al., 2009). In cryosections neurons were 
considered TRPA1-positive if the mean fluorescence intensity (measured in arbitrary units, 
AU) was higher than the mean background fluorescence plus four times the SD measured 
from at least 10 random unstained cells. For TRPA1 labeling the analysis was performed 
using three different TRPA1 antibodies (as described above), which gave similar results. 
Neurons were considered positive for the other labels if the mean fluorescence intensity 
(measured in AU) was higher than the mean background fluorescence plus three times the 
SD measured from at least 10 random unstained cells. Only sections that were at least 70 µm 
apart were considered to avoid double counting neurons. Only for presentation purposes 





2.1.12 RNA isolation and quantitative PCR (qPCR) 
Total RNA was isolated from freshly dissociated DRG neurons of AnxA2-/- and WT mice by 
NucleoSpin RNA XS (Macherey-Nagel) according to the manufacturer’s instructions. One 
thousand nanograms of total RNA were then used for first-strand cDNA synthesis using 
QuantiTect reverse transcription kit (Qiagen). First, genomic DNA (gDNA) was eliminated 
adding gDNA wipe-out buffer and incubating the mix at 42 °C for 6 minutes in a thermal 
cycler (Bio-Rad T100). Reverse transcription (RT) master mix (Quantiscript RT buffer, RT 
primer mix, Quantiscript reverse transcriptase) was then added, followed by incubation at  
42 °C for 30 minutes and  95 °C for 3 minutes to finally obtain cDNA. TRPA1 gene expression 
was assessed in both genotypes by real-time qPCR using the SYBR green system (Power SYBR 
Green PCR Master Mix; Life Technologies) in a LightCycler 480 instrument (Roche). The 
melting curve analysis of amplified product was used to confirm the specificity of qPCR 
assay. All samples were run in triplicate and control reactions were run without template 
and with the reverse-transcription reaction reagents as negative controls. Threshold cycle 
(Ct) values, the cycle number in which SYBR green fluorescence rises above background, 
were normalized to two reference genes (β-actin and GAPDH) and recorded as a measure of 
initial transcript amount. Primer sequences 5’-3’ are the following: 
 
TRPA1 (fw: CCATGACCTGGCAGAATACC; rev: TGGAGAGCGTCCTTCAGAAT); 
β-actin (fw: GATCAAGATCATTGCTCCTCCTG; rev: CAGCTCAGTAACAGTCCGCC);  
GAPDH (fw: CAATGAATACGGCTACAGCAAC; rev: TTACTCCTTGGAGGCCATGT). 
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2.1.13 TRPA1 live labeling 
TRPA1 live labeling was essentially performed as described previously (Schmidt et al., 2009). 
Freshly dissociated neurons of AnxA2-/- mice and WT littermates were nucleofected with 
TRPA1-IRES-YFP, AnxA2, or empty plasmid for rescue experiments and maintained in culture 
for 36 h. Surface TRPA1 was live labeled by incubating neurons with TRPA1 antibodies (1:25) 
for 60 minutes followed by five washes in neuronal medium and incubation with secondary 
antibodies conjugated to Alexa Fluor 546 (Life Technologies) at a dilution of 1:200. Neurons 
were washed with PBS, fixed in 2% PFA/PBS for 20 minutes, and imaged on a Zeiss Axio 
Observer Z1 epifluorescence microscope. All groups to be compared were processed in 
parallel using the same culture preparation. The image analysis was performed as described 
previously (Schmidt et al., 2009) with the following change: as a reference for background 
signal we added ROIs in the non-labeled area along the ROI, which delineated the periphery 
of each neuron. This enabled us to determine a threshold value of intensity (in AU) above 
which the label was considered positive for each individual neuron. Only for presentation 
purposes were brightness, contrast, and curve levels of paired images (i.e., corresponding 




2.1.14 Mouse behavior 
All animals were housed in a temperature-controlled environment under a 12 h light/dark 
cycle with food and water provided ad libitum. Behavioral tests were performed by 
individuals blind to genotype. In these tests 6- to 12-week-old WT and AnxA2-/- littermates 
were used and the mice were matched for gender. AnxA2-/- mice were kindly provided by 
Katherine A. Hajjar (Ling et al., 2004). Mice were acclimatized for 30 minutes (injection 
paradigms) or 120 minutes (thermal and mechanical paradigm) in a transparent Plexiglas 
box. For injections, 10 µl of experimental agent were injected subcutaneously into the 
plantar surface of one hindpaw. Nocifensive behaviors were assessed by measuring the time 
spent licking, flicking, or lifting the injected paw for 10 minutes. Vehicle injection (PBS) did 
not elicit any significant pain behavior in either genotype (data not shown). Mechanical and 
thermal sensitivity were measured according to standard procedures (Minett et al., 2011) 
and according to the manufacturer’s manual (Ugo Basile). 
Mechanical sensitivity was determined upon paw withdrawal to application of a graded 
force (0–10 g in 40 s for basal acute sensitivity and 0–7.5 g in 40 s for the inflammatory pain 
paradigm) via a dynamic aesthesiometer (Ugo Basile) to the plantar surface of both 
hindpaws. Paw withdrawal latencies were averaged from at least four readings per paw.  
To determine thermal sensitivity two different tests were used: heat and cold sensitivity. 
Heat sensitivity. The paw withdrawal latency to infrared heat (set at 40) was measured using 
a plantar test apparatus (Hargreaves apparatus; Ugo Basile). Paw withdrawal latencies for 
each test were averaged from at least four readings per paw. 
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Cold sensitivity. A custom-made cold plate was set at 1.5 °C and the latency to the onset of 
nocifensive behaviors (licking, flicking, or lifting of the injected paw) and escape behaviors 
(jumping) were measured. If mice did not show nocifensive behaviors (as observed often 
after vehicle injection) they were removed from the cold plate after 5 minutes and scored 
with a latency of 330 s. All groups to be compared were assessed in parallel. All animal 
experiments were approved and performed in compliance with the institutional guidelines 





2.1.15 Statistical analysis 
The nonparametric Mann–Whitney test or the two-tailed unpaired Student‘s t test were 
used for single comparisons, and one-way ANOVA was used for multiple comparisons. All 
values refer to mean ± SEM; n indicates the sample number, p denotes the significance 
(*<p0.05, **<p0.01, ***<p0.001) and refers to the respective control in each experimental 




2.2 TRPA1 interactome undergoes dramatic changes during 
inflammatory pain  
2.2.1 Inflammatory pain paradigm and TRPA1 immunoprecipitation from tissue 
lysates 
Inflammatory pain was induced in male C57BL/6J mice (6-12 weeks old) by injection of 10 µl 
of Complete Freund’s Adjuvant (CFA) into the plantar surface of the left hindpaw, with PBS-
injected mice serving as control. Mice were sacrificed 24 h after the injection by CO2 
inhalation followed by decapitation according to guidelines stated in the German Animal 
Welfare Act. Ipsilateral lumbar DRGs (L1 to L5) were dissected and collected in PBS with 
protease inhibitors. Tissue was subsequently homogenized in 500 µl/sample ice-cold 
solubilization buffer (100 mM NaCl, 50 mM Tris-HCl pH 7.4, 320 mM sucrose, 1mM DTT, 1% 
DDM, complete protease inhibitor cocktail) using first a glass dounce homogenizer and 
subsequently shearing the lysate passing it 10 times through a 20G needle and 10 times 
through a 25G needle. DRGs from 20 mice per condition were necessary for each 
experimental replicate, and tissue from TRPA1-/- animals (ipsilateral and contralateral lumbar 
DRGs from 10 non-injected mice) was processed in parallel. Lysates were then incubated for 
1 h at 4 °C on a tube rotator (VWR International) followed by centrifugation for 10 minutes 
at 2500xg at 4 °C. A pre-clearing step was performed incubating each lysate with 50 µl 
magnetic beads (Protein G Dynabeads; Life Technologies) for 1 h at 4 °C on a tube rotator. 
Beads were then removed and the lysate incubated with 24 µg of TRPA1 antibodies (rabbit, 
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E1; (Schmidt et al., 2009)) for 4 h at 4 °C on a tube rotator. Magnetic beads (100 µl/sample) 
were then added to the lysates and incubated overnight at 4 °C on a tube rotator. After one 
short washing step with ice-cold solubilization buffer, beads were then eluted by incubation 
for 10 minutes at 70 °C in 40 µl of elution buffer containing the following: 1X TG PRiME 




2.2.2 Protein identification by mass spectrometry analysis and database search 
Eluted proteins were separated on precast TG PRiME Tris/glycine 8-16% gradient gels (Serva) 
and visualized by colloidal Coomassie staining. Entire gel lanes were cut into 24 equally-sized 
gel pieces and subjected to automated in-gel digestion with trypsin as described previously 
(Schmidt et al., 2013). Tryptic peptides were dried down in a vacuum centrifuge, re-dissolved 
0.1% trifluoro acetic acid and spiked with 2.5 fmol/μL of yeast enolase 1 tryptic digest 
standard (Waters Corporation) for quantification purposes (Silva et al., 2006). After 
nanoscale UPLC separation, tryptic peptides were subjected to mass spectrometry analysis 
using a Synapt G2-S quadrupole time-of-flight mass spectrometer equipped with ion mobility 
option (Waters Corporation). Positive ions in the mass range m/z 50 to 2000 were acquired 
with a typical resolution of at least 20,000 FWHM (full width at half maximum) in the ion 
mobility-enhanced data-independent acquisition (DIA) mode (Geromanos et al., 2012; Silva 
et al., 2005) with drift time-specific collision energies (Distler et al., 2014). For protein 
identification, continuum LC-MS data were processed (including lock mass correction) and 
searched using Waters ProteinLynx Global Server version 3.0.2 (Li et al., 2009). A custom 
database was compiled by adding the sequence information for yeast enolase 1 and porcine 
trypsin to the UniProtKB/Swiss-Prot mouse proteome and by appending the reversed 
sequence of each entry to enable the determination of false discovery rate (FDR). UniProtKB 
release 2014_10 (16,686 entries) was used for replicate experiment 1 and 2, while 2015_01 
(16,695 entries) was used for replicate experiment 3. Precursor and fragment ion mass 
tolerances were automatically determined by PLGS 3.0.2 and were typically below 5 ppm for 
precursor ions and below 10 ppm (root mean square) for fragment ions. 
Carbamidomethylation of cysteine was specified as fixed and oxidation of methionine as 
variable modification. One missed trypsin cleavage was allowed. The FDR for protein 
identification was set to 1% threshold. For post-identification analysis, the freely available 
software ISOQuant (http://www.isoquant.net) was used to merge the 24 LC-MS datasets per 
gel lane and to calculate the absolute in-sample amounts for each detected protein 
according to the TOP3 quantification approach (Distler et al., 2014; Kuharev et al., 2015). 
Based on the peptides identified in the first PLGS database search round described above, 
the stringency for reporting a protein was increased further by considering only peptides 
with a minimum length of six amino acids, which were identified with scores above or equal 
to 5.5. FDR for both peptides and proteins was set to 1 % threshold and only proteins 
reported by two and more peptides were quantified using the TOP3 method. This part was 
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performed by the Proteomics Group at Max Planck Institute of Experimental Medicine (Head 




2.2.3 Data analysis 
For mass spectrometry analysis, the final volume of tryptic digestion reactions could vary 
based on the protein concentration of the sample, hence a first level of normalization was 
applied to rule out this variable. In fact, the amount of each detected protein was multiplied 
by the ratio between the total volume of the digest and the volume later injected into the 
LC-MS/MS system. For comparable analysis of the amount of all detected proteins within 
each single biological replicate, data were normalized to account for potential differences in 
the amount of bait (TRPA1) identified between the CFA and VEH samples. Specifically, in the 
sample where less bait was detected, the amount of each identified protein would be 
multiplied by the ratio of “higher bait amount/lower bait amount” between the two 
samples. Then, this normalized value was used to calculate the ratio of the amount in each 
sample (VEH or CFA) relative to the TRPA1 KO one (VEH/KO and CFA/KO), as well as the 
ratios CFA/VEH and VEH/CFA. Subsequently, for selection of proteins coimmunoprecipitating 
with TRPA1 with high specificity and strong evidence, we set the following stringent criteria: 
(1) detected in each of the three biological replicates; (2) in each replicate, identified with 
amount at least three times greater than what found in the relative TRPA1 KO sample. Only 
candidates fulfilling both the above criteria were considered as high confidence TRPA1-
binding partners and used for further statistics and bioinformatics analysis. We then further 
classified such candidates as: 
-Only identified in CFA: if fulfilling above criteria in three replicates in CFA samples only; 
-Only identified in VEH: if fulfilling above criteria in three replicates in VEH samples only; 
-Identified in both: if fulfilling above criteria in three replicates in both VEH and CFA. 
Gene ontology analysis was performed by uploading gene IDs into the functional annotation 
tool of the DAVID (Database for Annotation, Visualization and Integrated Discovery) 
bioinformatics resource, to assign genes with their affiliate terms and to order them by 
enrichment (Huang da et al., 2009a, b). In order to visualize molecular interaction networks 
based on known and predicted associations among proteins we uploaded Uniprot accession 
numbers of all proteins in each dataset into STRING (Search Tool for the Retrieval of 
Interacting Genes/Proteins) (Jensen et al., 2009). The whole analysis was made by choosing 









2.3 NIPSNAP1 and Nocistatin modulate TRPA1 channels 
Most experiments were performed by Master student Oli Abate Fulas under the author´s 
teaching and supervision; therefore part of the methods is adapted from Oli´s Master thesis. 
 
2.3.1 HEK293T cell culture and transfection  
HEK293T cells were maintained at 37 °C, 5% CO2 in DMEM+GlutaMAX containing 10% FBS 
and penicillin/streptomycin. Transient transfections were performed using FuGENE HD 
(Promega) following manufacturer’s instructions, and cells plated on 1 mg/ml poly-D-lysine 
and 20 μg/ml laminin-coated coverslips. For testing the specificity of NIPSNAP1 antibody 0.5 
µg of NIPSNAP1-myc-DKK (Origene) was used. For calcium imaging and 
immunocytochemistry experiments measuring the effect of NIPSNAP1 overexpression, 0.6 
µg of TRPA1-myc cotransfected with 0.5 µg of either NIPSNAP1-myc-DKK or empty vector 




2.3.2 Dissociated mouse dorsal root ganglion neuron culture  




2.3.3 Nucleofection of DRG cultures 
Transfection of neurons was achieved by nucleofection of cDNA into freshly isolated DRG 
neurons using the P3 Primary Cell 4D Nucleofector X Kit with the 4D-Nucleofector X Unit 
according to the manufacturer’s instructions (Lonza AG). For NIPSNAP1 knock-down a final 
concentration of 500 nM of NIPSNAP1 siRNA mix or scramble control siRNA were used to 
transfect cells. NIPSNAP1 siRNA mix details: 
 
Name Cat. # Target sequence Company 
Mm_Nipsnap1_3 SI01327837 ACGAATCATGATTCCTCTGAA Qiagen 
Mm_Nipsnap1_4 SI01327844 TTCCTACATAATGTGGTTAAA Qiagen 
Mm_Nipsnap1_5 SI04919999 TCCGTCATCTCCAGGACATAA Qiagen 
Mm_Nipsnap1_6 SI04920006 CACCACTTATGGGCCTACAAA Qiagen 
 
For immunocytochemistry experiments testing the effect of NIPSNAP1 overexpression for 
TRPA1 expression, neurons were cotransfected with 0.5 µg of TRPA1-IRES-YFP and 0.5 µg of 
either NIPSNAP1-myc-DKK or empty vector. For live labeling experiments cultures were 
transfected with 0.5 µg of TRPA1-IRES-YFP. After nucleofection, neurons were allowed to 
recover in RPMI medium for 10 minutes at 37 °C before plating in growth medium. Two 
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hours after transfection half of the growth medium was exchanged with fresh medium and 
neurons were grown for 24-72 h, based on the experiment. 
 
 
2.3.4 RNA isolation and quantitative PCR (qPCR) 
Total RNA extraction was performed on DRG neurons 72 h after nucleofection with 
NIPSNAP1 siRNA or scramble control using NucleoSpin RNA XS (Macherey-Nagel) according 
to the manufacturer’s instruction. Two hundred and fifty nanograms of total RNA were then 
used for first-strand cDNA synthesis using QuantiTect reverse transcription kit (Qiagen).  
First, genomic DNA (gDNA) was eliminated adding gDNA wipe-out buffer and incubating the 
mix at 42 °C for 2 minutes in a thermal cycler (Bio-Rad T100). Reverse transcription (RT) 
master mix (Quantiscript RT buffer, RT primer mix, Quantiscript reverse transcriptase) was 
then added, followed by incubation at 42 °C for 30 minutes and  95 °C for 3 minutes to finally 
obtain cDNA. NIPSNAP1 gene expression was assessed by real-time qPCR using the SYBR 
green system (Power SYBR Green PCR Master Mix; Life Technologies) in a LightCycler 480 
instrument (Roche). The melting curve analysis of amplified product was used to confirm the 
specificity of qPCR assay. All samples were run in triplicate and control reactions were run 
without template as negative controls. Threshold cycle (Ct) values, the cycle number in 
which SYBR green fluorescence rises above background, were normalized to two reference 
genes (β-actin and GAPDH) and recorded as a measure of initial transcript amount. Primer 
sequences 5’- 3’ are the following: 
 
NIPSNAP1 (fw: GGGTGCTGTGCGCTTCTATT; rev: TCCAGACATTCGGGCTTCAC); 
β-actin (fw: GATCAAGATCATTGCTCCTCCTG; rev: CAGCTCAGTAACAGTCCGCC); 





DRG cultures or HEK293T cells were first fixed for 20 minutes in 4% PFA and blocked with 
10% donkey serum and 0.4% Triton X-100 in PBS for 1 h at room temperature, followed by 
incubation with primary antibody overnight at 4 °C in 1% donkey serum 0.1% Triton X-100 in 
PBS. Cells were then washed five times with PBS and incubated with secondary antibodies 
(1:250) for 2 h at room temperature in 1% donkey serum 0.1% Triton X-100 in PBS. Cells 
were washed again five times with PBS before mounting with SlowFade Gold reagent (Life 
Technologies). For quantification of knock-down efficacy, NIPSNAP1 siRNA- and control 
siRNA-nucleofected DRG cultures were labeled with primary anti-NIPSNAP1 (rabbit; 1:100; 
Abcam) and secondary anti-rabbit Alexa488 (donkey; Life Technologies). For testing antibody 
specificity, HEK293T cells transfected with NIPSNAP1-myc-DKK cDNA were coimmunostained 
with primary anti-NIPSNAP1 (rabbit; 1:100; Abcam) and anti-myc (mouse; 1:100; Santa Cruz 
Biotechnology) and secondary anti-rabbit Alexa488 (donkey; Life Technologies) and anti-
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mouse Alexa647 (donkey; Life Technologies). For testing effect of NIPSNAP1 overexpression 
for TRPA1 expression, DRG cultures transfected with TRPA1-IRES-YFP and either NIPSNAP1-
myc-DKK or empty vector were costained with primary anti-TRPA1 (rabbit; 1:50) and anti-
GFP (chicken; 1:500; Life Technologies) and secondary anti-rabbit Alexa546 (donkey; Life 
Technologies) and anti-chicken Alexa647 (goat; Life Technologies). For the same purpose, 
HEK293T cells cotransfected with TRPA1-myc and either NIPSNAP1-myc-DKK or empty vector 
were colabeled for TRPA1 with anti-TRPA1 (rabbit; 1:100) and for NIPSNAP1 with anti-Flag 
(mouse; 1:100; Sigma Aldrich) and secondary anti-rabbit Alexa488 (donkey; Life 





Mice (ages 6–12 weeks) were killed with CO2. DRG were carefully dissected, collected in 4% 
PFA/PBS, and fixed overnight at 4 °C. After cryoprotection in 30% sucrose/PBS overnight 
tissues were frozen in optimal cutting temperature compound, sectioned as step serial 
sections with a cryostat at 10 µm width, mounted on SuperFrost Plus slides, and stored at -
80 °C. Frozen slides were thawed at room temperature for 30 minutes, washed three times 
in PBS with 0.4% Triton X-100 (PBT), blocked for 30 minutes in PBT containing 5% goat or 
donkey serum, and incubated overnight at 4 °C with primary antibodies diluted in antibody 
solution (1% donkey or goat serum and 0.1% Triton X-100 in PBS).  Sections were stained 
with anti-NIPSNAP1 (rabbit; 1:200; Abcam) and 1:100 anti-Peripherin (chicken; 1:100; 
Abcam). The next day, after washing five times in PBS, corresponding secondary fluorescent 
antibodies: anti-rabbit Alexa488 (donkey; 1:250; Life Technologies) and anti-chicken 
Alexa555 (donkey; 1:250; Life Technologies) were applied and incubated for 2 h at room 
temperature in antibody solution. Sections were then washed five times in PBT and mounted 




2.3.7 Image acquisition and analysis of immunostainings 
Digital images of the stained cultures and DRG cryosections were obtained by an 
epifluorescence microscope (Zeiss Axio Observer Z1). Images for all experimental groups 
were taken using identical acquisition parameters. All groups to be compared were 
processed simultaneously using the same culture or tissue preparation.   Raw images were 
analyzed by using NIH ImageJ essentially as described previously (Schmidt et al., 2009). Cells 
were considered positive for their labeled protein (NIPSNAP1, TRPA1 or Peripherin) if the 
mean fluorescence intensity (measured in arbitrary units, AU) was higher than the mean 
background fluorescence plus three times the SD measured from at least 5 random 




2.3.8 Ratiometric calcium imaging 
Ratiometric calcium imaging was performed essentially as described previously (Coste et al., 
2010) using an inverted microscope (Zeiss Axio Observer Z1). Briefly, cells were washed 
three times with calcium imaging buffer consisting of 1×HBSS (1.3 mM Ca2+) supplemented 
with 10 mM HEPES. A working solution of the ratiometric Ca2+ indicator dye Fura-2 was 
prepared resuspending 50 µg of Fura-2 AM cell permeant (Life Technologies) in 50 µl DMSO 
and adding additional 50 µl Pluronic F-127 (Life Technologies) and then diluting the mix 
1:200 in imaging buffer. Cells were incubated with the dye for 30-60 minutes at 37 °C, 
according to the manufacturer´s recommendations. Cells were then washed again three 
times prior to imaging. Fura-2 fluorescence was measured by illuminating the cells with an 
alternating 340/380 nm excitation light. Fluorescence intensity was measured at 510 nm for 
both excitation wavelengths and the intracellular Ca2+ concentration expressed as the 
A340/A380 ratio. All experiments were conducted at room temperature 24-72 h after plating. 
Experiments on the subject of examining the effect of Nocistatin on TRPA1-mediated 
response were performed with this protocol: 2 minutes application of 10 μM 
Nocistatin/vehicle followed by 2 minutes application of 10 μM Nocistatin/vehicle in 25 μM 
MO and then incubation for 4 minutes. Subsequently, 50 μM MO, 1 μM capsaicin and 60 
mM KCl were applied in the mentioned order for 2 minutes each with 5 minutes of 
intervening washes between the stimuli. For experiments dealing with the influence of 
Nocistatin on TRPV1: pre-incubation with 10 μM Nocistatin (applied for 2 minutes) was 
followed by application of 10 μM Nocistatin/vehicle in 0.1 μM capsaicin and incubation for 4 
minutes. After 5 minutes of washing 1 μM capsaicin was applied for 2 minutes. HEK293T 
cells overexpressing TRPA1 and either NIPSNAP1 or empty vector were assessed for TRPA1 
response via application of 1 μM/10 μM/30 μM MO for 2.5 minutes followed by washing 
with imaging buffer for 5 minutes and subsequent application of 100 μM MO for 3 minutes. 
For data analysis, threshold for activation was set at 20% above the baseline obtained from 
averaging five time points immediately before addition of each stimulus. All experimental 
groups to be compared were processed in parallel using the same culture preparation. At 
least two coverslips from three independent culture preparations were analyzed per 




2.3.9 TRPA1 live labeling 
TRPA1 live labeling was essentially performed as described previously (Schmidt et al., 2009). 
Freshly dissociated neurons were nucleofected with TRPA1-IRES-YFP and maintained in 
culture for 36 h. Cells were then incubated with 10 µM Nocistatin or vehicle for 4 minutes at 
room temperature, washed and immediately after surface TRPA1 was live labeled by 
incubation with TRPA1 antibodies (1:25) for 60 minutes followed by five washes in neuronal 
medium and incubation with secondary antibodies conjugated to Alexa Fluor 546 (Life 
Technologies) at a dilution of 1:200. Neurons were washed with PBS, fixed in 2% PFA/PBS for 
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20 minutes, and imaged on a Zeiss Axio Observer Z1 epifluorescence microscope. All groups 
to be compared were processed in parallel using the same culture preparation. The image 
analysis was performed as described previously (Schmidt et al., 2009) with the following 
change: as a reference for background signal we added ROIs in the non-labeled area along 
the ROI, which delineated the periphery of each neuron. This enabled us to determine a 
threshold value of intensity (in AUs) above which the label was considered positive for each 




2.3.10 Statistical analysis 
The two-tailed unpaired Student‘s t test was used to evaluate statistical significance. All 
values refer to mean ± SEM; p denotes the significance (*<p0.05, **<p0.01) and refers to the 

































3.1 Annexin A2 (AnxA2) regulates TRPA1-dependent nociception 
The gross part of the text relative to this section is based on (Avenali et al., 2014).  
 
3.1.2 AnxA2 is a binding partner of TRPA1 in mouse sensory neurons 
A crucial determinant of TRPA1 activity and function could be represented by the network of 
protein complexes associated to the channel, the so-called TRPA1 interactome. In this line 
we aimed to identify TRPA1-binding candidates by affinity purification of the native TRPA1 
channels from mouse sensory neurons. The choice of working with native channels was 
result of important considerations: on the one hand, this means dealing with the need of a 
significant amount of tissue, but on the other hand, it has considerable advantages with 
respect to, for instance, systems where the channel is overexpressed, namely a reduction of 
false negative hits and more reliable candidate list. In this line sensory neurons were 
dissected from mice and whole cell lysates obtained by mild detergent solubilization. This 
procedure is critical and needs to be carefully optimized in terms of the stringency of the 
buffer and the washing steps that will follow. We needed to obtain a reasonable amount of 
the bait (TRPA1) that, by its own nature and as other transmembrane proteins, is 
hydrophobic, and therefore difficult to isolate. On the one hand, with too harsh conditions 
we would end up disrupting complexes and potentially losing weak and transient 
interactions, likely biologically relevant. On the other hand, being too mild would result in 
insufficient amount of TRPA1 protein and incomplete removal of non-binding proteins, 
which will be then detected during mass-spectrometry analysis, making the candidate list 
hard to interpret. From cell lysates, TRPA1 channels were affinity purified with specific 
TRPA1 antibodies and rabbit IgG serving as control. An antibody with high specificity and 
affinity for the target protein is an essential tool for the success of coimmunoprecipitation 
experiments; accordingly, a custom-made antibody has been used, which performance and 
specificity in tissue from TRPA1-deficient mice had been already proved in previous 
publications (Schmidt et al., 2009). Eluates of coimmunopreciptation were separated by 1D-
PAGE, gel lanes were excised, subjected to “in-gel” digestion with trypsin, and samples 
submitted to mass-spectrometry analysis. This procedure enabled the detection of 
endogenous TRPA1 channels validating such approach (Fig. 4). In addition to the bait, a 
consistent list of potential interacting partner was obtained and the selection of candidates 
for further characterization was based on stringent criteria. We only considered proteins 
that: (1) appeared in both independent biological replicates of the experiment; (2) were 
identified with a minimum of two unique peptides; and (3) were absent in both independent 
control replicates. This strategy led to the identification of Annexin A2 (AnxA2) as a binding 
partner of TRPA1 in mouse sensory neurons (Fig. 4). AnxA2 is a member of the Annexin 
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superfamily of calcium- binding proteins and is involved in different membrane transport 





Figure 4: AnxA2 coimmunoprecipitates with native TRPA1 from mouse sensory neurons. 
The table depicts the MS/MS results (identified peptides and number of total spectra) of two independent 
TRPA1-affinity purifications and corresponding controls. The mass spectrometry analysis was performed by the 




3.1.2 AnxA2 coimmunoprecipitates with TRPA1 in a heterologous expression 
system  
In order to validate AnxA2 as a TRPA1-binding protein we tried to recapitulate the 
interaction in a well-established and widely accepted heterologous expression system, 
namely HEK293T cells. We transfected HEK293T cells with myc-tagged TRPA1 (TRPA1-myc) 
and mouse AnxA2 cDNA, and performed TRPA1 immunoprecipitation. Nicely, we could 
detect AnxA2 in the eluate when both anti-myc (Fig. 5A) and anti-TRPA1 antibodies (data not 
shown) were used for immunoprecipitation. HEK293T cells transfected with TRPA1-myc and 
the empty vector were used as a negative control (TRPA1+Mock; Fig. 5A). These data 
supports the MS results indicating that this interaction can be reproduced in a non-neuronal 
context and suggest that it could be potentially direct, or at least that does not involve a 
neuronal cell-specific mediator. To get better insights into the nature of the interaction, we 
attempted to identify the AnxA2 domain involved in the association with TRPA1 and 
therefore cloned a truncated version of AnxA2, called ΔAnxA2. This construct lacks the first 
15aa of the native protein, a region already implicated in AnxA2-protein-protein 
interactions, and did not immunoprecipitate with TRPA1 upon overexpression in HEK293T 
cells (Fig. 5A). These findings suggest that the first 15 residues of AnxA2 are critical to the 
binding to TRPA1 channels, either directly or via yet to be identified proteins. AnxA2 can be 
found associated with its best characterized binding partner p11 (also referred to as 
S100A10), a member of the EF-Hand superfamily of calcium-binding proteins. p11 itself has 
been reported to interact and modulate the activity of several ion channels (Donier et al., 
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2005; Okuse et al., 2002; Svenningsson et al., 2006), among them some TRP channels, like 
TRPV4 (Ning et al., 2012), TRPV5, and TRPV6 (van de Graaf et al., 2003). We therefore found 
of interest to test whether p11 binds TRPA1 and potentially acts as a mediator of the 
interaction with AnxA2. However, immunoprecipitation experiments in HEK293T cells 
transfected with TRPA1 and p11 did not reveal any interaction between the two (Fig. 5B), 
and this is in line with our proteomics data in sensory neurons that did not identify p11 as a 
potential TRPA1-interacting protein. In sensory neurons TRPA1 is well known to be 
coexpressed to a large extent with the heat and capsaicin receptor TRPV1. The activity of the 
two channels influences each other and general nociceptor excitability, and they have also 
been reported to interact and form heteromers (Fischer et al., 2014; Staruschenko et al., 
2010). Interestingly, immunoprecipitation in HEK293T cells expressing TRPV1 and AnxA2 did 
not show any physical association between the two (Fig. 5C), which points to a certain 






Figure 5: AnxA2 coimmunoprecipitates with TRPA1 in a heterologous expression system. 
A–C, Representative Western blots (WB) of immunoprecipitation (IP) experiments in HEK293T cells 
recombinantly expressing the indicated constructs. A, AnxA2 is detected in eluates (E) of immunoprecipitations 
only upon cotransfection of TRPA1-myc and AnxA2 (TRPA1-myc+AnxA2) but not in control conditions (TRPA1-
myc+Mock). A deletion construct of AnxA2 lacking the first 15 aa (ΔAnxA2) did not coimmunoprecipitate with 
TRPA1 (TRPA1 myc+ΔAnxA2). Immunoprecipitations were performed with myc antibodies. B, P11 did not 
coimmunoprecipitate with TRPA1 in our assay (TRPA1-myc+p11). Immunoprecipitations were performed with 
myc antibodies. C, AnxA2 did not coimmunoprecipitate with TRPV1 in cotransfected HEK293T cells (TRPV1 + 
AnxA2) while TRPV1 itself is readily immunoprecipitated. Immunoprecipitations were performed with TRPV1 







3.1.3 AnxA2 does not affect biophysical properties of recombinant TRPA1 
channels 
The physical association of AnxA2 to TRPA1 might have functional consequences for TRPA1 
activity and function. The channel might undergo conformational changes or be subjected to 
chemical modification (e.g. phosphorylation) that would affect its response to activating 
stimuli. To test this hypothesis we asked whether AnxA2 affects the biophysical properties of 
TRPA1 channels expressed in HEK293T cells, a well-established system to assess TRPA1 
activity (Bandell et al., 2004; Jordt et al., 2004; Macpherson et al., 2007; Meseguer et al., 
2014). TRPA1 is a promiscuous channel responsive to a wide variety of agonists, both 
endogenous and exogenous, and it is also intrinsically voltage-dependent to a certain 
degree. We studied both channel properties by whole-cell patch clamp recordings. First, we 
transfected HEK293T cells either with TRPA1 (TRPA1+Mock) or with TRPA1 and AnxA2 
(TRPA1+AnxA2) and measured the voltage-dependent activation properties of TRPA1 
channels upon membrane depolarization (Meseguer et al., 2014; Zhou et al., 2013). As 
shown in figure 6, AnxA2 expression did not change the intrinsic voltage-dependent 
activation profile of TRPA1 channels (Fig.6A,B). TRPA1 current density measured at -75 mV 
(following depolarization at +175 mV) was not affected by AnxA2 overexpression (TRPA1 + 
Mock: 71.8 ± 6.9 pA/pF; TRPA1 + AnxA2: 75.3 ± 8.1 pA/pF). Furthermore, neither activation 
nor inactivation time constants were different when AnxA2 was present (TRPA1 + Mock: 
19.3 ± 4.3 ms and 46.7 ± 3.1 ms; TRPA1 + AnxA2: 19.3 ± 5.5 ms and 52.6 ± 6.1 ms, for 
activation and inactivation, respectively). We then studied TRPA1 activation properties 
following stimulation with mustard oil (MO), a well-known specific TRPA1 agonist (Bandell et 
al., 2004; Bautista et al., 2006; Macpherson et al., 2007; Zhou et al., 2013). 
Electrophysiological analysis showed that neither the MO-dependent I/V relationship nor 
activation and inactivation time constants were altered by AnxA2 overexpression (Fig.6C,D). 
Next, we asked whether the cellular responses to TRPA1 activation by the specific agonist 
MO is affected by AnxA2 overexpression (Fig.6E,F). Figure 6F shows that the dose 
dependency of MO-evoked increase of [Ca+2]i is very similar in both conditions, and together 
with the electrophysiology data show that AnxA2 overexpression does not alter properties 








Figure 6: AnxA2 neither affects TRPA1 voltage dependence nor cellular responses to the TRPA1 agonist MO. 
A, B, AnxA2 does not affect the voltage dependence of TRPA1. A, Whole-cell currents in response to voltage 
steps applied to HEK293T cells expressing TRPA1 (TRPA1+Mock) or TRPA1+AnxA2. B, Average ± SEM voltage 
dependence of TRPA1 peak tail currents at -75 mV for indicated transfections. For each transfection condition 
data were separately normalized to the current obtained after the maximum depolarization level (+175 mV). C, 
Representative currents elicited by I/V ramps after mustard oil (MO) application of 25 µM MO for indicated 
transfections. D, Left, representative MO-induced current at -70 mV (holding potential). Right, Average ± SEM 
time constants of MO-induced activation and inactivation measured by a mono-exponential fit to the currents 
obtained at -70 mV for indicated transfections (n>12 cells per condition; n.s.; Student’s t-test). E, AnxA2 does 
not affect cellular responses to the TRPA1 agonist MO. Representative images of ratiometric [Ca+2]i 
measurements in HEK293T cells expressing TRPA1 (TRPA1+Mock) or TRPA1 and AnxA2 (TRPA1+AnxA2). GFP 
was cotransfected to visualize transfected cells for further analysis. The image shows the cellular response to 
10 µM MO (MO). One hundred micromolar ATP was applied after MO to control for cellular health; ≥500 cells 
analyzed for each MO concentration; n.s.; Student’s t-test. Scale bar, 10 µm. F, Dose dependency of MO-
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evoked increase of cellular [Ca+2]i. All data are represented as mean ± SEM. Electrophysiology recordings were 




3.1.4 AnxA2 is coexpressed with TRPA1 in nociceptors 
In order to gather more information and investigate deeper the potential influence of AnxA2 
association for TRPA1 function, we moved to a physiological cellular setting, i.e., sensory 
neurons of dorsal root ganglia (DRG). Within DRGs, different subpopulation of primary 
afferents can be classified, which properties reflect, among others, the range of stimuli 
transduced and the speed of signal transmitted.  Non-myelinated small diameter neurons 
generally transmit nociceptive signals and can be identified by the expression of the 
intermediate filament Peripherin. (Patapoutian et al., 2009). Myelinated neurons show 
instead bigger diameter, mostly signal innocuous stimuli, and express the heavier 
Neurofilament 200 (NF200). To get insights into AnxA2 localization we characterized its 
expression pattern in rodent DRGs. First of all we confirmed the specificity of the commercial 
AnxA2 antibody, as indicated by the absence of signal in tissue from AnxA2 deficient mice 
(Ling et al., 2004) compared to WT littermates (Fig.7A,B). Then, we measured AnxA2 
expression and observed it in 30.1 ± 1% of mouse DRG neurons, of which 66 ± 1.7% showed 
coexpression with Peripherin (Fig.7A). This enrichment of AnxA2 in a subpopulation of small 
non-myelinated neurons is consistent with previous reports (Naciff et al., 1996). Since AnxA2 
binds to TRPA1, the two proteins should be coexpressed in sensory neurons. For 
colocalization studies we had to obviate to the problem that both TRPA1 and AnxA2 
antibodies had been raised in the same species. For this reason we shifted to using a mouse 
AnxA2 antibody in rat tissue.  In rat DRGs AnxA2 showed an expression profile very similar to 
the mouse counterpart, with 27 ± 0.7% positive neurons, of which 68 ± 1.9% coexpressed 
Peripherin (Fig.7C). Only a small fraction (5 ± 0.5%) showed colocalization with NF200, 
marker for big myelinated neurons (Fig.7D). Importantly, TRPA1 expression was comparable 
with previous reports using the same antibodies (Schmidt et al., 2009) or different ones 
(Bautista et al., 2005) and could be detected in 16.2 ± 1.5% of rat DRG neurons. In line with 
our hypothesis, the costaining with AnxA2 revealed an interesting degree of colocalization in 
rat DRGs, with 53 ± 1.4% of TRPA1-positive neurons also expressing AnxA2 (Fig.7E). It is 
relevant to note that the actual degree of coexpression cannot be unambiguously 
determined, as these TRPA1 antibodies have been shown to preferentially label neurons 
with relatively high TRPA1 expression (Huang et al., 2012; Schmidt et al., 2009). These data 
altogether demonstrate that AnxA2 is expressed in a nociceptive subpopulation of DRG 








Figure 7. AnxA2 is coexpressed with TRPA1 in nociceptors.  
A, B, Representative images of immunohistochemistry on cryosections of mouse DRG colabeled for AnxA2 and 
Peripherin in WT mice (A) and AnxA2-/- (B) littermates; ≥3000 neurons analyzed; Scale bar, 20 µm. C–E, 
Representative images of immunohistochemistry on cryosections of rat DRG colabeled for AnxA2 and 
Peripherin, NF200, or TRPA1, respectively; ≥5000 neurons analyzed. White arrows indicate examples of 
neurons coexpressing AnxA2 and TRPA1. Scale bar, 40µm. From (Avenali et al., 2014). 
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3.1.5 AnxA2-/- mice exhibit increased TRPA1 expression in sensory neurons 
Probably the most commonly used and direct way to get insights into the role and function 
of a protein is via a loss of function approach and investigating the resulting phenotype. In 
this line we aimed to determine the consequences of AnxA2 deletion for DRG neurons, 
therefore, we assessed potential variations in different neuronal subpopulations by 
measuring the expression of specific markers. Immunohistochemistry in DRG cryosections 
revealed an interesting increase in the number of TRPA1-positive neurons in AnxA2-/- mice 
compared with WT littermates (WT: 8.1 ± 0.4%; AnxA2-/-: 13.6 ± 0.5%; Fig.8). At the same 
time however, we could not detect any significant change for either neurofilament 
characterizing myelinated and non-myelinated neurons, namely NF200 and Peripherin 
(Fig.8). No appreciable difference was measured also in the number of cells immunoreactive 
for TRPV1, the heat and capsaicin receptor that, as already discussed, is highly coexpressed 
and in many ways related to TRPA1 (Fig.8). Noteworthy, the values we obtained in terms of 
TRPA1 expression in DRGs of naïve mice are in line with what reported by other publications 
using the same antibodies (Huang et al., 2012; Schmidt et al., 2009). In conclusion, these 
data suggest a specific increase of TRPA1-positive cells in DRG neurons from AnxA2-/- mice, 
without general alteration in the expression of other markers. Additionally, qPCR-based 
measurement of TRPA1 mRNA levels did not show any difference between genotypes (data 
not shown), suggesting an alternative mechanism, potentially post-translational, at the base 











Figure 8. AnxA2-/- mice exhibit more TRPA1-
positive DRG neurons.  
A,B, Representative images (A) and 
quantification (B) of immunohistochemistry on 
DRG cryosections from AnxA2-/- mice and WT 
littermates labeled for TRPA1, Peripherin, 
NF200, and TRPV1 as indicated; ≥3000 
neurons analyzed; p=0.0009. Student’s t test. 
Scale bar, 20µm. All data are represented as 





3.1.6 TRPA1 responses are sensitized in a subset of AnxA2-/- sensory neurons 
The interpretation of the immunohistochemistry analysis results showing more TRPA1-
positive neurons in AnxA2-/- mice is open to different interpretations: on the one hand, it 
could be the result of de novo expression of TRPA1 in additional neurons compared to WT; 
on the other hand, it could be due to an increase of TRPA1 levels in neurons already 
expressing the channel. In the latter case in fact, this increase would facilitate the detection 
by TRPA1 antibodies and result in a higher number of measured immunoreactive cells. In 
addition, as previously mentioned, our TRPA1 antibodies have already been described to 
exhibit limited sensitivity and therefore preferentially label neurons with high TRPA1 
abundance (Huang et al., 2012; Schmidt et al., 2009). To address this dilemma, we turned to 
an antibody-independent approach to investigate TRPA1 channels activity: ratiometric 
calcium imaging in cultured sensory neurons. This technique allows the study of the 
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dynamics of intracellular calcium levels and in our case can be exploited to monitor the 
activity of calcium-permeable channels (like TRPA1 and TRPV1) in response to specific stimuli 
(Bautista et al., 2006; Schmidt et al., 2009). In our case we used mustard oil (MO), a TRPA1 
specific agonist (Bautista et al., 2006; Jordt et al., 2004), to compare the consequences of 
TRPA1 activation between AnxA2-/- mice and WT littermates. Within DRG neurons, TRPA1 
expression varies among cells and spinal levels, and it is quite heterogeneous (Schmidt et al., 
2009; Vandewauw et al., 2013), therefore we decided to stimulate the cells with different 
concentrations of MO: 1) a low or subsaturating concentration (12 µM) able to activate only 
neurons showing high TRPA1 expression; 2) a saturating one (50 µM) that will activate all 
TRPA1-expressing cells, and therefore allow quantitative comparison of the total population 
between genotypes.  As figure 9 shows, we measured a significant increase in the number of 
neurons responding to the subsaturating MO pulse in AnxA2-/- cultures respect to WT. At the 
same time however, the number of responders to the saturating pulse of MO, activating all 
TRPA1 expressing cells, was not different between genotypes. These data show that in 
AnxA2-/- DRGs there is a neuronal subpopulation that is more responsive to MO, while the 
total population of TRPA1-expressing cells is not changed respect to WT. Moreover, we 
observed that cellular responses to capsaicin, a TRPV1-specific agonist, are not changed 
between genotypes. This, together with the facts that the amplitude of responses to the 
stimuli (Fig.9D) are not affected, and that TRPA1 desensitization mediated by MO 
(homologous) or capsaicin (heterologous) are unchanged (data not shown), suggest that 
deletion of AnxA2 might have a specific effect on TRPA1 in a subpopulation of nociceptive 
neurons. To further support these findings, and confirm that this effect was specifically 
dependent on AnxA2, we performed a rescue experiment to re-establish AnxA2 function in 
deficient neurons. To this end, we transfected AnxA2-/- DRG cultures with mAnxA2 or control 
plasmid (Mock). Strikingly, AnxA2 re-expression restored the WT phenotype in AnxA2-/- DRG 
cultures, meaning the number of responders to the subsaturating pulse of MO was now 
comparable to WT, and at the same time the responsiveness to the saturating MO 
concentration or capsaicin (Fig. 9E) and the response amplitudes were similar between 
conditions (Fig. 9F). Together these results support a role of AnxA2 in the modulation of 
TRPA1 channels in a subpopulation of nociceptive neurons, while the total prevalence of 










Figure 9. TRPA1 responses are sensitized in a subset of AnxA2-/- sensory neurons.  
A–F, AnxA2-/- DRG cultures are more sensitive to low MO concentrations as measured by ratiometric calcium 
imaging. A, The graph depicts the percentage of responders to 12 µM, 25 µM, or 50 µM MO (12 µM, AnxA2-/-: 
21.5 ± 1.5 compared with WT: 11.4 ± 1.7%, p=0.0008, Student’s t test; n≥500 neurons for each MO 
concentration from N=3 independent cultures each). B, Representative averaged traces from all neurons in one 
coverslip (including responders and non-responders to applied stimuli) upon application of indicated stimuli. C, 
Quantification of the percentage of neurons responding to each stimulus (MO; 12 µM, see data in A; 50 µM, 
AnxA2-/-: 34.5 ± 1.9 compared with WT: 32 ± 2.7%, n.s.; Cap 0.5 µM, AnxA2-/-: 22.6 ± 2.8 compared with WT: 
19.9 ± 2.9%, n.s.; ≥500 neurons per condition, N=3 independent cultures each). D, Quantification of response 
amplitudes to each stimulus (measured as peak increase over baseline). E, F, Quantification of the percentage 
of neurons responding to each stimulus (E) and the response amplitudes (F ) in Mock-transfected WT neurons 
(WT Mock), Mock-transfected AnxA2-/-neurons (AnxA2-/- Mock), and AnxA2-/- neurons transfected with AnxA2 
cDNA (AnxA2-/- rescue). Twelve micromolar MO (WT Mock: 17.1 ± 2.2, AnxA2-/- Mock: 25.9 ± 3.4, AnxA2-/-
rescue: 12.4 ± 2.8; *p0.05, **p0.01, ANOVA with Newman–Keuls test; ≥250 neurons per condition; N=3 




3.1.7 AnxA2 limits TRPA1 plasma membrane expression in sensory neurons 
In AnxA2-/- DRG cultures more neurons responded to the low MO pulse respect to WT, but 
the response to the high MO concentration was unchanged. Considering the heterogeneous 
expression of TRPA1 in DRG, this outcome could reflect an increase in the number of 
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channels at the plasma membrane in some neurons, which would explain the enhanced 
responsiveness to MO. At full-blowing high saturating concentration of MO, all TRPA1-
expressing cells would be responding to the stimulation, thereby masking this difference.  To 
test this hypothesis we aimed to identify and quantify selectively TRPA1 channels at the cell 
surface of sensory neurons by live labeling TRPA1 with specific antibodies targeting 
extracellular epitopes of the channel. Unfortunately these very same reagents are not 
suitable to effectively label the low abundant native TRPA1 population in DRG cultures under 
normal conditions. To overcome this technical problem, we first nucleofected WT and 
AnxA2-/- DRG neuron cultures with recombinant mTRPA1. Live labeling results showed that, 
in line with our hypothesis, AnxA2-/- neurons displayed an increase of signal at the plasma 
membrane, indicating more TRPA1 channels at the cell surface (Fig.10A). Very nicely, this 
effect could be rescued by re-expression of AnxA2 in deficient neurons, which restored the 
membrane signal to a level comparable to WT cultures (Fig.10B). In further support to these 
data, we performed whole cell patch clamp recordings to measure the entity of TRPA1-
mediated currents upon stimulation with the specific agonist MO. Indeed, we measured 
bigger currents in AnxA2-/- DRG neurons compared with WT neurons (again cultures were 
nucleofected with recombinant mTRPA1 to keep same conditions of live labeling 
experiments). Time constants of activation and deactivation did not seem to be affected and 
showed similar values between genotypes (Fig.10C,D). Altogether these data support a 




















Figure 10. AnxA2 restricts TRPA1 membrane levels in cultured DRG neurons.  
A, B, DRG cultures from AnxA2-/-mice and WT littermates were nucleofected with mTRPA1 (top) or 
conucleofected with AnxA2 cDNA (AnxA2-/- rescue; control: AnxA2-/- Mock; bottom) and subjected to live 
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labeling to selectively visualize TRPA1 channels at the plasma membrane. Representative images (A) and 
quantification (B) of live labeling (TRPA1 nucleofection: p=0.0004, Mann–Whitney test; n=50 cells per 
genotype, N=5 independent cultures each; AnxA2/Mock conucleofection: p=0.0115, Mann–Whitney test; n=40 
cells per genotype, N=4 independent cultures each). Scale bar, 10 µm. All data are represented as mean ± SEM. 
C, Representative whole-cell current traces of MO-gated currents at -70 mV in DRG neurons nucleofected with 
mTRPA1 (black trace: WT; gray trace: AnxA2-/-). The upper bar indicates the addition of 5 µM MO to the 
recording chamber. D, Left, Average ± SEM of current density after MO application measured at the current 
peak in each genotype (p=0.007, Student’s t test; n>12 neurons; N=3 cultures each). Right, Time constants of 
MO-induced activation and inactivation measured by a mono-exponential fit to the currents obtained at -70 
mV for each genotype (n.s.; n>12 neurons; N=3 cultures each). Electrophysiology recordings were performed 




3.1.8 TRPA1-dependent nocifensive behaviors are enhanced in AnxA2-/- mice 
Previous studies have reported a correlation between TRPA1 expression in sensory neurons 
and the degree of nocifensive responses in certain animal pain models (Obata et al., 2005; 
Schmidt et al., 2009; Zhou et al., 2013). Therefore, we asked whether the regulation of 
TRPA1 membrane level by AnxA2 has functional consequences for nociceptive signaling in 
vivo.  In this line we investigated the result of AnxA2 knock-down for the response of mice to 
acute mechanical, thermal and chemical stimulation. Mechanical sensitivity was measured 
using a dynamic plantar aesthesiometer, which applies a ramp of defined force to the mouse 
hindpaw by means of a blunt probe. The time from application of the stimulus to the 
reaction of the animal was recorded, and, as shown in figure 11A resulted in no significant 
difference between WT and AnxA2-/- littermates. Thermal sensitivity was assessed in a 
similar way, but using a Hargreaves plantar test apparatus which uses an infrared source of 
heat in place of the mechanical probe. Nonetheless this test showed again similar responses 
in mice of both genotypes (Fig.11A). Next, we tested the mouse response to selective TRPA1 
activation, by injecting the animal with a solution of the specific agonist MO into the plantar 
surface of the left hindpaw, and assessed the resulting nocifensive response. Specifically, this 
means observing the animal in a certain time window following the injection (10 minutes in 
this case) and quantifying the time the animal spends licking, flicking or lifting the injected 
paw as a result of the perceived pain. Very interestingly and in line with the in vitro data, 
AnxA2-/- mice showed to be more sensitive to MO injection, resulting in a significant increase 
in nocifensive behavior respect to WT littermates (Fig.11B). Notably, this effect was 
dependent on the concentration of MO injected, with high MO concentrations (60 mM) 
eliciting equally pronounced nocifensive responses in AnxA2-/- and WT mice (Fig.11B). At this 
high concentration we observed strong and long-lasting nocifensive behavior also in WT 
mice, which can be related to what we observed in calcium imaging studies, where full 
activation of all cells expressing TRPA1 would potentially mask the phenotype observed at 
lower concentrations. In fact, stimulation with saturating MO concentrations would cause all 
TRPA1-expressing neurons, independently of TRPA1 abundance, to be strongly activated and 
consequently result in similar neuronal and behavioral responses in WT and AnxA2-/- mice, as 
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indicated by our results. We also probed TRPV1-mediated nociception performing injections 
of the respective specific agonist capsaicin and, importantly, found no difference in the 
elicited nocifensive response between genotypes (Fig.11B). Several studies demonstrated a 
contribution of TRPA1 to specific hypersensitivity states in conditions of inflammatory pain 
(Bautista et al., 2006; da Costa et al., 2010; del Camino et al., 2010; Obata et al., 2005; Petrus 
et al., 2007; Zhou et al., 2013). Therefore, we investigated the possible impact of AnxA2 on 
TRPA1 function during inflammatory pain using the well-established Complete Freund’s 
Adjuvant (CFA) model in mice (da Costa et al., 2010; Obata et al., 2005; Petrus et al., 2007; 
Zhou et al., 2013). In this model CFA is injected into the plantar surface of one of the mouse 
hindpaws and leads to long-lasting inflammation and development of hypersensitivity to 
thermal (to hot and cold temperatures) and mechanical stimuli. At least in the first 48 h 
following the injection, TRPA1 has been shown to contribute to cold hypersensitivity (da 
Costa et al., 2010; Obata et al., 2005), while it is dispensable for heat hypersensitivity 
(Bautista et al., 2006; Petrus et al., 2007) and its role for innocuous mechanical 
hypersensitivity is still debated (da Costa et al., 2010; Petrus et al., 2007; Zhou et al., 2013). 
As expected CFA injection reduced the withdrawal latency of the animals on a cold plate, 
indication of cold allodynia; however, consistent with the view of AnxA2 modulating TRPA1 
activity, AnxA2-/- mice showed enhanced hypersensitivity to cold respect to WT littermates, 
indicated by the even lower latency times recorded (Fig.11C).  In addition, figure 11D shows 
how CFA induced allodynia in the mice also in response to heat and mechanical stimulation, 
but in this case to a similar degree in both genotypes. Contralateral (non-injected) paws 
were not affected and did not develop hypersensitivity after CFA injection (Fig.11D). These 
results clearly demonstrate that AnxA2 modulation of TRPA1 extends to the in vivo context, 








Figure 11. Enhanced TRPA1-dependent nocifensive behaviors in AnxA2-/- mice.  
A, Quantification of the latency of withdrawal of both hindpaws when WT mice and AnxA2-/- littermates were 
subjected to radiant heat (Heat) or punctuate mechanical pressure (Heat: n=10 mice each; Mechanical: n=9 
mice each; n.s., Student’s t test). B, Quantification of the response duration of acute nocifensive behavior over 
10 minutes after injection of different concentrations of MO (10 mM: WT 11.8 ± 1.9 s compared with AnxA2-/- 
18.5 ± 1.6 s, n=10 mice each; p=0.0126, Student’s t test; 30 mM:  59.9 ± 15.9 s, n=8 mice compared with AnxA2-
/- 177.4 ± 28.5 s, n=11 mice; p=0.0009, Student’s t test; 60 mM: WT compared with AnxA2-/-, n=7 mice each; 
p=0.5064, n.s., Student’s t test), and after injection of 3 µg Cap (WT compared with AnxA2-/-; n=9 mice each; 
p=0.4040, n.s., Student’s t test). C, D, WT mice and AnxA2-/- littermates were unilaterally injected with CFA to 
elicit inflammatory pain. C, Quantification of the latency of nocifensive/escaping behaviors when mice were 
placed on a cold plate 24 h after vehicle injection (V; n=8 mice each; n.s.) and CFA-injection (WT CFA: 165.7 ± 
17.1 s, n=15 mice; AnxA2-/- CFA: 75.2 ± 19.3 s, n=13 mice; **<p0.01 comparing values of CFA of the injected 
paw between genotypes; #<p0.05 and ###p<0.001 comparing values of V and CFA of the injected paw within 
each genotype, ANOVA with Bonferroni’s multiple-comparison test). D, Quantification of the latency of 
withdrawal of the injected hindpaw and non-injected hindpaw when mice were subjected to radiant heat (left) 
or punctuate mechanical pressure (right) after vehicle injection (n=8 mice each; n.s.) and CFA-injection (Heat: 
n=5 mice each; n.s. between genotypes; Mechanical: n=9 mice each, n.s. between genotypes; ####p<0.0001 
comparing values of V and CFA of the injected paw within each genotype, ANOVA with Bonferroni’s multiple-
comparison test). Non-injected paws did not develop hypersensitivity after CFA and did not differ between 





3.2 TRPA1 interactome undergoes dramatic changes during 
inflammatory pain 
3.2.1 Identification of TRPA1-protein complexes in different conditions 
The identification and characterization of AnxA2 as a protein interacting with TRPA1 and 
modulating its activity supports our hypothesis that protein-protein interactions are indeed 
important determinants of TRPA1 function. In addition, this work paves the way for a more 
thorough investigation of the potential dynamic changes in TRPA1-associated protein 
complexes in different pain states. We therefore aimed to identify how different interacting 
partners and/or quantitative changes within the same complex could contribute to the 
modulation of TRPA1 channels function in specific pain conditions. This multi-step approach 
starts with the careful selection of animal pain models, as the basis for performing the 
interactomics screening. Numerous pain paradigms modeling features of clinically relevant 
conditions (e.g. inflammatory and neuropathic pain) have been developed for mouse and rat 
studies. As previously discussed TRPA1 has been reported in several studies to contribute to 
the modulation of hypersensitivity during inflammatory pain (Bautista et al., 2006; da Costa 
et al., 2010; del Camino et al., 2010; Obata et al., 2005; Petrus et al., 2007; Zhou et al., 2013); 
in addition to the results we obtained supporting TRPA1-involvement in CFA-induced 
allodynia (paragraph 3.1.8), these considerations led us to choose this animal pain model for 
the interactomics screening (Fig.12A). In this line mice were subjected to CFA injection into 
the plantar surface of one hindpaw, and the development of inflammation was controlled. 
The hypersensitivity that accompanies this inflammatory state peaks at 24 h (as measured by 
dynamic planar aesthesiometer at different time points), at which time the animals were 
sacrificed for tissue collection. Lumbar DRG containing the cell bodies of neurons innervating 
the ipsilateral paw (L1 to L5) were dissected and whole cell lysates obtained by detergent 
solubilization. Native TRPA1-protein complexes were harvested by immuno-affinity 
purification using TRPA1-specific antibodies, processed as described in detail in the methods 
section, and submitted to state-of-the-art quantitative mass spectromertry analysis. DRG 
from mice subjected to vehicle injection (VEH) were used as control. As a further control for 
potential unspecific binding of some proteins in the immunoprecipitation step, the same 
procedure was performed using tissue from TRPA1-/- mice, where the bait is therefore 
absent, and which results will be used in the analysis step (described below) to remove false-
positive hits. The data-independent acquisition (DIA) proteomics approach we chose for 
sample analysis has several advantages over the so-called “shotgun mass spectrometry“, 
namely more depth of acquisition and significantly reduced under-sampling.  In addition, we 
aimed at not only qualitatively investigating our samples, but also identify quantitative 
changes in TRPA1-protein complexes, which requires the choice of an appropriate 
quantification method. We chose label-free intensity-based quantification that, in 
comparison to techniques based on stable isotope labeling, presents major advantages as 
low sample demand, no costs for labeling reagents, and a high coverage of both, the 
individual protein sequences and the overall proteome. One factor of utmost importance for 
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reliable label-free quantification is sample preparation, which has to be accurately 
performed in order to minimize variability, as the samples are not mixed at any time (in 
contrast to approaches based on stable isotope labeling). To address this issue, sample 
preparation was done in parallel for all experimental conditions within each biological 
replicate. Subsequently, peptide intensity-based quantification was performed according to 
the so-called Top3 method, where each in-gel digest is spiked with a control digest of known 
concentration and analyzed by LC-MS in the data-independent acquisition mode. This whole 
procedure was validated by the consistent identification of endogenous TRPA1 channels in 
both VEH and CFA samples, whereas the samples from TRPA1-/- animals were void of it 










Figure 12. Identification of TRPA1-protein complexes during inflammatory pain 
A, Representation of the experimental workflow followed for the interactomics screening of TRPA1-protein 
complexes during inflammatory pain. B, The table depicts the MS/MS results (identified peptides and sequence 
coverage) of three independent TRPA1-affinity purifications and corresponding controls. C, Cartoon 
representing an idealized outcome of the study, with TRPA1 associated with different binding partners in the 
different conditions. Three biological replicates were performed. Mass spectrometry analysis was performed in 
collaboration with Olaf Jahn (Proteomics Group, Max-Planck Institute of Experimental Medicine, Göttingen). 





3.2.2 Mass spectrometry screening reveals significant changes in TRPA1-protein 
complexes during inflammatory pain 
Mass spectrometry is an extremely powerful tool able to get plentiful information about the 
composition of a sample and can generate long lists of identified proteins, but proper and 
accurate analysis is essential for robust reliability of the data. In order to get datasets of 
proteins with strong evidence of binding to the bait, we decided to set stringent criteria for 
the analysis of the mass spectrometry results. Only proteins fulfilling both the following 
criteria were considered as high-confidence TRPA1-interacting partners for further analysis: 
1) Detected in each of the three biological replicates; 
2) In each replicate, identified with amount at least three times greater than what 
found in the relative TRPA1 KO sample. 
We then classified the proteins fulfilling the criteria above as: 
 Only identified in CFA: if fulfilling above criteria in three replicates in CFA samples 
only; 
 Only identified in VEH: if fulfilling above criteria in three replicates in VEH samples 
only; 
 Identified in both: if fulfilling above criteria in three replicates in both VEH and CFA 
samples. 
In this way we obtained a list of selected proteins binding TRPA1 specifically in the context of 
inflammatory pain (CFA model) that we could differentiate from the control condition. These 
findings revealed a dramatic alteration of TRPA1 interactome, as shown in figure 13A. The 
Venn diagram shows very little overlap between the two conditions (VEH and CFA) indicating 
that TRPA1 interactome critically reshapes, with many binding partners substituted by 
others that are likely to modulate TRPA1 activity and function in specific ways. A complete 
list of all selected proteins can be found in Appendix. In order to get a better overview and 
more information on the obtained data, we performed a gene ontology (GO) analysis using 
the DAVID functional annotation tool to assign genes with their affiliate GO terms and to 
order them by enrichment (Huang da et al., 2009a, b). Figure 13B shows protein ontology 
categories for “biological process (BP)” and “cellular component (CC)” represented by 
proteins identified in the “Only in CFA” dataset. GO analysis for the “Only in VEH” dataset is 



















Figure 13. TRPA1 interactome undergoes dramatic changes during inflammatory pain 
A, Venn-diagram shows the number of identified candidates in either condition. All considered candidates fulfill 
the following criteria: >3x enriched compared to KO in all replicates; detected in all 3 replicates in each 
respective condition. B, Gene ontology (GO) analysis using the DAVID functional annotation tool shows 
significantly enriched (p<0.05) categories for “biological process (BP)” and “cellular component (CC) 




Identifying known and predicted associations among proteins of the same dataset is a 
relevant piece of information and can be visually represented by STRING (Jensen et al., 2009) 












Figure 14. STRING association networks of single datasets 
STRING confidence network views are based on known and predicted functional associations between proteins 
of the datasets “Only in VEH” (A) and “Only in CFA” (B). 
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A common way to visualize the large datasets generated by quantitative proteomics 
experiments is using the so-called volcano plots, which display the distribution of identified 
proteins according to the p-value (-log10 transformed) and the fold change (log2 
transformed). Analyzing volcano plots allows to easily highlight hits that show large fold 
changes and low p-values, and can therefore be helpful in the selection of high priority 
candidates for follow-up and validation (Oveland et al., 2015). Therefore, in parallel to our 
analysis based on the above-mentioned criteria, we found worthwhile to try to visualize our 
complete dataset in this way, relating the p-value of the comparison of CFA and VEH 
conditions with the respective fold change. For our specific dataset, the realization of such a 
kind of plot intrinsically implies that all proteins have been detected in the three biological 
replicates in both conditions. Since it was not the case for many, we had to obviate to this 
issue by setting a value of 0.001 (one order of magnitude lower than the limit considered for 
detection) to all non-identifications. The graph obtained (Fig.15) displays each single protein 
identified in the three biological replicates as a spot which coordinates are derived from the 
fold change of CFA respect to vehicle conditions, and the level of significance (p-value). In 
order to identify the most interesting candidates we defined arbitrary cut-off values as: 
(1) CFA/VEH ratio ≥1.3 (corresponding to log2 CFA/VEH ≥ 0.38; red vertical line): the 
protein shows enrichment in CFA. 
(2) CFA/VEH ratio ≤0.7 (corresponding to log2 CFA/VEH ≤ -0.51; cyan vertical line): the 
protein shows enrichment in VEH. 
We can observe that an important number of protein showed enrichment in either 
condition, and if we then relate this information to the p-value (p<0.05; -log p-value > 1.30; 
horizontal dashed line), it is clear that a fraction reaches statistical significance (39 hits). If 
we then compared this fraction with the results of our previous analysis, we clearly see that 
the overlap is very limited. In fact only 4 proteins out of 55 identified in first analysis (ONLY 
in VEH + ONLY IN CFA, see fig.13A), the ones shown as red spots in figure in figures 15, show 
a significantly low p-value (p<0.05). 
  
 
Figure 15. Volcano plot of quantitative proteomics data 
Each protein identified in the three biological replicates is represented by a single spot. On the Y axis is 
reported the –log10 of the comparison between CFA and VEH values from the single replicates. On the X axis is 
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reported the log2 of the ratio between mean CFA and mean VEH, each calculated from the average of the three 
biological replicates. A value of 0.001 (one order of magnitude lower than the limit considered for detection) 
was set to all non-identifications. The red vertical line represents a value of 0.38 (corresponding to CFA/VEH 
ratio 1.3) and the cyan vertical line a value of -0.51 (corresponding to CFA/VEH ratio 0.7). The horizontal dashed 
line represents a value of 1.3 (corresponding to p-value 0.05). Red spots indicate hits that show significant 
regulation according to the volcano plot, and also fulfill criteria set in previous analysis (fig.13A). The cyan spot 
represents a hit that shows significant regulation according to the volcano plot, but does not fulfill criteria set 
in previous analysis (fig.13A). 
 
This shows the limitations of using such a way of analyzing our dataset. In fact, the p-value 
can easily become not significant where it happens that data present quite some variability, 
or a protein fails to be identified in certain conditions. This can indeed be the case for the 
dataset generated by our experiment, where sample preparation is long and complex, and 
even involves in vivo behavioral paradigms. Because of this intrinsic variability, a relevant 
part of the proteins were in fact identified only in some conditions. Theoretically, we could 
avoid applying the 0,001 value to all non-identifications and measure only the proteins 
identified in all three biological replicates in both conditions, but in this way we would end 
up with only a fraction of the hits and not a faithful representation of the data in our hands. 
This suggests that for the visualization of our dataset the use of a p-value would have only 
limited benefit. In addition, a visualization of the data in this way results in the loss of a 
crucial piece of information that was instead included in our previous analysis, which is the 
TRPA1 KO (KO) condition. This is reflected by the fact that all the other proteins in figure 15 
that show p-value lower than 0.05 (35 out of 39), and so look potentially interesting from the 
volcano plot, do not fulfil the criteria to be selected in our previous analysis. One example is 
the candidate represented by the cyan spot in figure 15, which indeed shows a significant 
difference between CFA and VEH conditions, but a suboptimal profile when related to the 
TRPA1 KO. We could therefore try to incorporate this piece of information for either VEH or 
CFA conditions, with the ratio CFA/VEH (or the reciprocal) showing enrichment, both 
reported as log2 of fold changes for better visualization (Fig.16). 
 
A             B 
 
Figure 16. Alternative scatter plots of quantitative proteomics data 
A,B, Each protein identified in the three biological replicates is represented by a single spot. On the Y axis is 
reported the log2 of the ratio between mean CFA and mean KO (A) or mean VEH and KO (B). On the X axis is 
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reported the log2 of the ratio between mean CFA and mean VEH (A) or the reciprocal (B). All ratio values were 
calculated from the average of the three biological replicates. A value of 0.001 (one order of magnitude lower 
than the limit considered for detection) was set to all non-identifications. The red vertical line represents a 
value of 0.38 (corresponding to CFA/VEH or VEH/CFA ratio 1.3). The horizontal dashed line represents a value 
of 1.58 (corresponding to CFA/KO or VEH/KO ratio 3). The red spot represents a hit that show relevant 
regulation according to this plot, but does not fulfill criteria set in previous analysis (fig.13A). 
 
 
To define a protein as identified only in the respective condition (VEH or CFA) but not in KO, 
an arbitrary cut-off was set: 
(1) CFA/KO ratio ≥ 3 corresponding to log2 CFA/KO ≥ 1.58; horizontal dashed line): only 
in CFA. 
(2) VEH/KO ratio ≥ 3 corresponding to log2 CFA/KO ≥ 1.58; horizontal dashed line): only 
in VEH. 
These plots show a consistent number of proteins that present enrichment in either 
condition (ratio CFA/VEH or Veh/CFA ≥1.3; red line) and were significantly identified in the 
respective condition relative to TRPA1 KO.  However, these plots present some issues. In fact 
the ratio values displayed represent mean values calculated as the average of the amount 
identified in each of the three biological replicates (again with 0.001 in case of non-
detection). In this way a protein like the one represented by the red spot in figure 16A would 
seem interesting, but instead looking more carefully into raw values we realize that it has 
been identified only once in CFA (in a relatively high amount) which does not support it as a 
priority hit in our case. In this way we are in fact not appreciating the information that would 
come from observing each single replicate, as we did in first analysis. While there is not a 
perfect way to analyze and display data like these, we can gather information from them all 
and use it in combination for the best possible selection of high priority candidates for 




3.3 NIPSNAP1 and Nocistatin modulate TRPA1 channels 
Most experiments were performed by Master student Oli Abate Fulas under the author´s 
teaching and supervision and are summarized in Oli´s Master thesis (indicated in every figure 
where applicable). 
 
3.3.1 NIPSNAP1 is abundantly expressed in nociceptors of mouse DRGs 
In a separate set of experiments we focused our attention on a protein called 4-
Nitrophenylphosphatase domain and non-neuronal SNAP25-like protein homolog 1 
(NIPSNAP1), which function is largely still unknown. In a screening for expression profile of 
several proteins in mouse DRGs, interestingly NIPSNAP1 antibody detected expression in 
42.2 ± 1.8% of sensory neurons. What really stood out was the degree of colocalization we 
measured with a well-known marker of small-diameter non-myelinated nociceptors, namely 
64 
 
the intermediate neurofilament Peripherin. In fact, 64.4 ± 1.4% of Peripherin-positive 
sensory neurons showed NIPSNAP1 expression (Fig.17), which could potentially suggest a 





 Figure 17. NIPSNAP1 is abundantly expressed in 
nociceptive neurons of mouse DRGs. 
A, B, Representative images (A) and quantification (B) 
of Immunohistochemistry on cryosections of mouse 
DRG colabeled for NIPSNAP1 and Peripherin. Scale bar, 
50 μm. ≥12000 neurons analyzed. All data are 
represented as mean ± SEM. Data from experiments 
performed by Master student Oli Abate Fulas under 





To validate the results of the immunohistochemical assays it was of primary importance 
testing the specificity of the antibody used to detect NIPSNAP1; in this line we transfected 
HEK293T cells with a vector expressing a myc-tagged construct of NIPSNAP1 and then 
coimmunostained the cells with antibodies against both NIPSNAP1 and myc. The stainings 
showed a beautiful colocalization of the signal from the two antibodies, confirming that this 






Figure 18. Validation of NIPSNAP1 antibody specificity 
Immunocytochemistry of NIPSNAP1 in HEK293T cells transfected with a vector expressing a myc-tagged 
construct of NIPSNAP1. The signals from NIPSNAP1 and myc antibodies overlap perfectly while non-transfected 
cells do not show any NIPSNAP1 signal. These results validate the specificity of the antibody against NIPSNAP1. 





3.3.2 Overexpression of NIPSNAP1 decreases TRPA1 expression in sensory 
neurons 
The role of NIPSNAP1 in a nociceptive subset of mouse DRG neurons can be manifold. 
Despite the handful of studies on NIPSNAP proteins and their potential roles, there is recent 
evidence indicating that NIPSNAP1 associates with TRPV6 channels in mouse liver cells, 
which results in a dramatic inhibition of the channel function, with currents virtually 
abolished  (Schoeber et al., 2008). NIPSNAP2, another member of the NIPSNAP family has 
instead been shown to modulate L-type Ca(2+) channels, and downstream CREB signaling, in 
a neuronal cell line (Brittain et al., 2012). These studies potentially suggest a role for the 
proteins of the NIPSNAP family in the regulation of ion channels. As already discussed, 
TRPA1 channels play an essential role as primary detectors of noxious stimuli in primary 
afferent nociceptors, where they are highly enriched (Patapoutian et al., 2009; Story et al., 
2003). Therefore it was interesting to note that the enriched expression of NIPSNAP1 in a 
subpopulation of small non-myelinated nociceptive neurons is likely to match, at least to a 
certain extent, the subset which expresses TRPA1. Unfortunately direct colocalization 
studies of the two proteins were not possible as both NIPSNAP1 and TRPA1 antibodies were 
raised in the same species. Hence we first aimed at investigating the consequences of 
NIPSNAP1 protein modulation for TRPA1 expression. The most common way to test the 
function of a protein is via a loss of function approach and knocking down its expression. 
However, different members of the NIPSNAP family are expressed in the nervous system 
(Buechler et al., 2004; Nautiyal et al., 2010; Schoeber et al., 2008; Tummala et al., 2010), one 
example being NIPSNAP2, which shares 75% homology with NIPSNAP1 (Nautiyal et al., 2010) 
and which, as mentioned,  has already been reported to modulate ion channels (Brittain et 
al., 2012). This concerned us about the possibility that, following NIPSNAP1 knock-down, 
compensatory mechanisms by other family members could mask a potential phenotype. For 
this reason we preferred to use a gain of function approach and tested the effect of 
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NIPSNAP1 overexpression for TRPA1 protein expression in sensory neurons via 
immunocytochemistry. Currently available TRPA1 antibodies are not suitable to effectively 
label the low-abundant native TRPA1 population in DRG cultures under normal conditions, 
therefore we nucleofected cultures of both genotypes with recombinant mTRPA1 and either 
NIPSNAP1 or empty vector. Very interestingly we measured a significant decrease in the 
number of TRPA1-immunoreactive cells in cultures overexpressing NIPSNAP1 (Mock: 35.7 ± 
1.6%; NIPSNAP1 OE: 28.4 ± 0.8%) as shown in figure 19. Importantly, this effect was not just 
an artifact due to saturation of the cell’s translational machinery upon NIPSNAP1 
overexpression, as the expression level of a cotransfected GFP marker was not affected. 
These data suggest a potential intriguing role of NIPSNAP1 in modulating TRPA1 expression 







Figure 19. DRG neuron cultures show less TRPA1-positive cells upon NIPSNAP1 overexpression 
A,B, Representative images (A) and quantification (B) of immunocytochemistry of mouse DRG neurons cultured 
for 24 h after transfection with TRPA1+Mock (Mock) or TRPA1+NIPSNAP1 (NIPSNAP1 OE) and stained with 
TRPA1 specific antibody; p=0.0158; Student’s t test; ≥2000 neurons analyzed per condition from N=3 
independent cultures. C,D, Representative images (C) and quantification (D) of GFP-positive cells. Scale bar, 







3.3.3 NIPSNAP1 decreases TRPA1 expression and activity in a heterologous 
expression system 
Motivated by these results, we speculated that this decrease in TRPA1-positive cells would 
be reflected by cellular calcium responses upon TRPA1 activation by the specific agonist MO. 
If the effect of NIPSNAP1 on TRPA1 activity is modest, it would be hard to reveal it by testing 
TRPA1 responses from the highly heterogeneous population of sensory neurons in DRG 
cultures. Therefore, in order to better study the contribution of NIPSNAP1 to TRPA1 activity 
and avoid the complications coming from DRG cultures that already express NIPSNAP1 and 
potentially other family members (Buechler et al., 2004; Nautiyal et al., 2010; Schoeber et 
al., 2008; Tummala et al., 2010), we aimed to employ a system where we could more 
selectively manipulate and study NIPSNAP1. HEK293T cells is a heterologous expression 
system that is widely used in the field, well established for overexpression studies of TRPA1 
and, as shown by the immunocytochemistry results in figure 18, does not show any 
detectable NIPSNAP1 expression. These features made of it a preferable candidate system 
for us to study the effect of NIPSNAP1 overexpression on TRPA1 activity. In this line we first 
of all wanted to confirm the same phenotype observed in sensory neurons, so we 
overexpressed mTRPA1 and either NIPSNAP1 or empty vector and, indeed, obtained 
comparable results, meaning a decrease of TRPA1-positive cells upon NIPSNAP1 
overexpression. While TRPA1 + Mock cotransfected HEK293T cells showed 27.7 ± 1.6% 
TRPA1-positive cells, this amount was reduced to just 16.2 ± 4.7% upon NIPSNAP1 
overxpression (Fig.20A,B). Next, we questioned whether this phenotype resulted in changes 
in TRPA1-mediated calcium responses by ratiometric calcium imaging. In order to test this, 
we used a protocol consisting of a first stimulation with a low concentration of MO (1, 10 or 
30 μM), followed by a saturating pulse (100 μM) that would activate all TRPA1-expressing 
cells. The results of these experiments showed that the response to the 1 μM MO 
application (normalized to the response to 100 μM MO) was significantly lower for 
NIPSNAP1-cotransfected cells (31.8 ± 2.4%) compared to mock-transfected ones (59.1 ± 
7.8%). On the contrary, the response elicited by higher concentrations of MO (10, 30, 100 
μM) remained similar between conditions (Fig.20C-F). These calcium imaging results indicate 
that overexpression of NIPSNAP1 does not induce changes in the number of cells that 
express TRPA1, but rather decreases cellular response to TRPA1 agonist, which is potentially 
due to changes in expression and/or activity of the channel. Together these findings suggest 



















            
 




























Figure 20. NIPSNAP1 decreases TRPA1 expression and activity in HEK293T cells 
A,B, Representative images (A) and quantification (B) of immunocytochemistry of TRPA1 in HEK293Tcells 
cotransfected with TRPA1 and either NIPSNAP1 (TRPA1+NIPSNAP1) or empty vector (TRPA1+Mock); p=0.047; 
Student’s t-test; Scale bar, 20 μm. C-F, Ratiometric calcium imaging shows that HEK293T cells coexpressing 
TRPA1 and NIPSNAP1 are less sensitive to low MO concentration. Representative traces (C) showing response 
to 1 µM MO; quantification of the percentage of neurons responding to each MO concentration (E) normalized 
to the total number of responders to 100µM MO (D); 1 μM MO (p=0.012); 10 μM MO (p=0.315); 30 μM MO 
(p=0.848); 100 μM (p=0.631). F, Comparison of mean amplitudes of calcium response to each MO 
concentration in HEK293T cells transfected with TRPA1 and either NIPSNAP1 or mock; Student’s t test; ≥370 
cells analyzed from N≥3 independent cultures; All data are represented as mean ± SEM. Data from experiments 






3.3.4 Nocistatin specifically sensitizes TRPA1 responses in sensory neurons  
A compelling recent study uncovered the physical association between NIPSNAP1 and 
Nocistatin, a neuropeptide already known to be involved in pain transmission (Okuda-
Ashitaka et al., 2012), even though its precise molecular function and mechanisms remain 
still unclear. In light of our current findings on the potential modulation of TRPA1 by 
NIPSNAP1, we decided to investigate whether Nocistatin is involved as well in TRPA1 
regulation. In this line we used ratiometric calcium imaging to measure the effect of 
Nocistatin on TRPA1-mediated cellular responses in DRG neuron cultures. Ten micromolar 
Nocistatin (Ahmadi et al., 2001; Ahmadi et al., 2003; Zeilhofer et al., 2000) was pre-applied 
and coadministered with two different concentrations of MO in order to investigate cellular 
response to both subsaturating and saturating stimuli. Interestingly, we measured a 
significant increase in the number of responders to 25 µM MO in the Nocistatin-treated 
group (24.4 ± 2.2%) compared to vehicle-treated controls (11.5 ± 2.2%), as shown in figure 
21A,B. In contrast, we could not observe any effect of Nocistatin treatment on the response 
elicited by different concentrations of capsaicin (0.1 µM and 1 µM), which probes TRPV1-
dependent calcium influx (Fig.21C,D). These findings reveal an enhancement of TRPA1-
mediated calcium response upon Nocistatin application and, together with the facts that 
response to capsaicin and response amplitudes were not changed, suggest a certain degree 




Figure 21. Nocistatin specifically modulates TRPA1-mediated calcium response in DRG neurons.  
A,B, Quantification of the percentage of neurons responding (A)  and mean amplitude of neuronal calcium 
response (B), after stimulation with 25μM MO or 50 μM MO along with 10 μM Nocistatin or vehicle. p=0.017; 
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Student’s t-test; ≥700 neurons analyzed from N=3 independent cultures. C,D, Nocistatin does not affect the 
percentage of responders (C) and mean amplitude response (D) to 0.1 μM and 1 μM capsaicin in DRG neuron 
cultures. All data are represented as mean ± SEM. Data from experiments performed by Master student Oli 




3.3.5 Nocistatin does not alter TRPA1 cell surface expression  
The increase we measured in TRPA1-mediated response upon Nocistatin treatment could be 
explained in different ways: (1) Nocistatin might directly sensitize TRPA1 or (2) Nocistatin 
could affect TRPA1 trafficking to the plasma membrane, where the channel is active and able 
to mediate calcium influx in response to activation. In this line, Nocistatin effect could be 
explained by an increase in TRPA1 plasma membrane expression, possibly due to enhanced 
trafficking to the membrane (this hypothesis implies that these new channels that reach the 
cell surface are functional), or decreasing internalization of the channels. To explore this 
possibility we aimed at live labeling selectively cell surface TRPA1 channels, an established 
procedure to study TRPA1 membrane levels in DRG neuron cultures (Schmidt et al., 2009). 
As already discussed in a previous chapter currently available TRPA1 antibodies are not 
suitable to effectively label the low-abundant native TRPA1 population in DRG cultures 
under normal conditions, therefore we first nucleofected cultures of both genotypes with 
recombinant mTRPA1, and then live labeled TRPA1 channels at the cell surface following 
Nocistatin treatment. Incubation with 10 µM Nocistatin in a way that recapitulates calcium 
imaging conditions, did not significantly alter TRPA1 label (Fig.22), indicating that TRPA1 cell 
surface expression is not changed and suggesting another mechanism through which 
Nocistatin enhances TRPA1-mediated calcium influx in sensory neurons.     
 
                                         
 
Figure 22. Nocistatin does not alter TRPA1 cell surface expression in cultured DRG neurons 
A, B, DRG neurons were nucleofected with mTRPA1, cultured for 24 h and treated with either 10 µM Nocistatin 
or vehicle, followed by live labeling to selectively visualize TRPA1 channels at the plasma membrane. 
Representative images (A) and quantification (B) of live labeling signal, similar between conditions; ≥30 cells 





3.3.6 Nocistatin’s effect on TRPA1 does not require NIPSNAP1  
As Nocistatin has been reported to interact with NIPSNAP1 (Okuda-Ashitaka et al., 2012), 
and with our results suggesting that both have potential modulatory activity on TRPA1-
mediated responses, we considered the possibility that the two binding partners act 
together in the regulation of TRPA1. Hypothetically, NIPSNAP1 might represent an 
intermediate element necessary for the increase in TRPA1-mediated responses induced by 
Nocistatin. In order to test this, we studied the consequences of NIPSNAP1 knock-down for 
Nocistatin-induced enhancement of MO responses via calcium imaging in DRG cultures. First 
and foremost, the efficacy of siRNA-mediated NIPSNAP1 knock-down was assessed at both 
mRNA (by qPCR) and protein level (by immunocytochemistry). From the qPCR studies we 
could evince that the relative expression of NIPSNAP1 mRNA declined by 75.7 ± 5% in 
cultures treated with NIPSNAP1 siRNA (Fig.23B). Accordingly, immunostainings showed that 
65.8 ± 2.7% of all neurons express NIPSNAP1 under control conditions, compared to 37.6 ± 
3.4% upon NIPSNAP1 knock-down (Fig.23A,C). These results, in addition to further affirm the 




Figure 23. NIPSNAP1 siRNA effectively knocks down the expression of NIPSNAP1 in DRG neuron cultures.  
A, Representative images of immunocytochemistry for NIPSNAP1 on DRG neuron cultures 3 days after 
transfection with NIPSNAP1 siRNA (NIPSNAP1 KD)  or scramble control siRNA (Control). The extent of NIPSNAP1 
knock-down after treatment with NIPSNAP1 siRNA was measured by qPCR (relative to housekeeping gene 
GAPDH) (B) and immunocytochemistry (C) (red arrowheads show examples of NIPSNAP1-positive neurons). 
≥700 neurons analyzed from N=3 independent cultures. Scale bar, 10 μm. p=0.002; Student’s t test. All data are 
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represented as mean ± SEM. Data from experiments performed by Master student Oli Abate Fulas under the 
author’s supervision. Figure A adapted from Oli’s Master thesis. 
 
We could then examine TRPA1-mediated calcium response with and without coapplication 
of Nocistatin upon knock-down of NIPSNAP1. The knock-down of NIPSNAP1 did not seem to 
affect the Nocistatin-induced enhancement of responses to 25 µM MO, which was still 
visible in both siRNA- and mock-transfected DRG cultures (Fig.24). Specifically, the number 
of responders showed a trend that reflect what observed in WT cultures treated with 
Nocistatin, although, because of the poor health of the cultures, it did not reach statistical 
significance in this set of experiments. In contrast, responses to 50 µM MO were similar 
between conditions, as well as response amplitudes. These results suggest that NIPSNAP1 is 
not necessary for the enhancement of TRPA1-mediated responses induced by its binding 
partner Nocistatin and additional rounds of the experiment will be performed to confirm this 




Figure 24. NIPSNAP1 knock-down does not seem to affect Nocistatin’s enhancement of TRPA1-mediated 
calcium response in DRG neuron cultures.  
A, Control siRNA-treated (Mock) DRG neurons show enhanced (p=0.134) calcium response to 25 μM MO upon 
coadministration of Nocistatin. B, The percentage of responders to 25 μM MO in NIPSNAP1-siRNA-transfected 
neurons (NIPSNAP1 KD) still shows an increase (p=0.124) upon Nocistatin treatment. C,D, Mean amplitude of 
response to either MO concentration is not altered in Mock-transfected (C) or NIPSNAP1 siRNA treated (D) 
cultures; ≥350 neurons analyzed per condition; Student’s t test. All data are represented as mean ± SEM. Data 





The transient receptor potential A1 (TRPA1) channel is an essential component of the 
molecular mechanisms that originate and modulate pain signaling in vertebrates. In 
nociceptive neurons where it is highly enriched, TRPA1 plays a fundamental role as a primary 
detector of noxious stimuli, by sensing a wide variety of exogenous and endogenous 
molecules with pro-inflammatory and pro-algesic properties. (Andrade et al., 2012; Bautista 
et al., 2013). TRPA1 has been implicated in the development and maintenance of 
hypersensitivity in a number of animal pain models, and is critically involved in different pain 
states (Nassini et al., 2014; Nilius et al., 2012). Regulation of TRPA1 activity is indeed one of 
the factors that translate in the reduced threshold and enhanced responsiveness of sensory 
neurons that contribute to the pathophysiology of clinically-relevant chronic pain syndromes 
(Schmidt et al., 2009). Even though TRPA1 activation modalities have been studied 
extensively, comprehensive knowledge on the mechanisms of TRPA1 regulation is still 
missing. This is especially true for the whole network of protein interacting with TRPA1 (the 
so-called TRPA1 interactome), which might constitute a potentially relevant contributor to 
channel activity and function. Considering the crucial role of TRPA1 in pain signaling, it is 
mandatory to shed light on the elusive molecular machinery regulating TRPA1 channels in 
sensory neurons. The principal aim of this study was therefore to contribute to our 
understanding of the mechanisms of TRPA1 regulation by identifying and characterizing 




4.1 Annexin A2 (AnxA2) regulates TRPA1-dependent nociception 
The gross part of the text relative to this section is based on (Avenali et al., 2014).  
 
A mass spectrometry-based proteomics approach led to the identification of the physical 
interaction of Annexin A2 (AnxA2) with native TRPA1 in mouse sensory neurons. We then 
used a combination of in vitro assays and in vivo mouse behavioral studies to demonstrate 
that AnxA2 is an endogenous modulator of TRPA1 membrane availability in sensory neurons, 
which in turn influences TRPA1-dependent animal pain response. Annexin A2 (or AnxA2) 
belongs to the Annexin superfamily of calcium-effector proteins, which encompasses several 
members with distinct architecture and broad range of functions. The biochemical hallmarks 
of the Annexins are the unique Ca2+ and lipid binding properties that endow them with the 
ability to associate with negatively charged phospholipids in a Ca2+-dependent and reversible 
manner. As a consequence, the functions of most Annexins are linked to their ability to 
interact with cellular membranes in a regulated fashion (Gerke et al., 2005). Like many other 
family members, AnxA2 is involved in a wide range of membrane trafficking processes and 
also contributes to the biogenesis of multivesicular bodies (Banks et al., 2011; Gerke et al., 
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2005; Luo and Hajjar, 2013). Many reports have highlighted the involvement of AnxA2 in 
delivering and retrieving various transmembrane proteins to and from the plasma 
membrane. For instance, AnxA2 is required for cAMP-induced aquaporin-2 (AQP2) 
translocation to the apical membrane in renal cells (Tamma et al., 2008), and its interaction 
with the Na(+)-K(+)-2Cl(-) cotransporter (NKCC2) mediates lipid-raft-dependent trafficking 
and therefore surface expression of the protein (Dathe et al., 2014). AnxA2 has also been 
reported to regulate β1 integrin internalization and degradation, suggesting an important 
role in modulating the cell-matrix adhesive properties of epithelial cells (Rankin et al., 2013). 
AnxA2 exerts its manifold functions in monomeric form or in heteromultimeric complexes 
with its best-known binding partner p11 (also designated S100A10), a member of the EF-
hand superfamily of calcium-binding proteins. The AnxA2-p11 complex plays a critical role in 
hemostasis: in endothelial cells it has been shown to bind tissue plasminogen activator 
accelerating the catalytic generation of plasmin. Plasmin in turn hydrolyzes insoluble fibrin, 
thus maintaining blood vessel patency. If this mechanism is impaired, fibrin accumulates and 
predisposition to blood clotting significantly increases (Kim and Hajjar, 2002). The AnxA2-p11 
complex also participates in Ca2+-evoked exocytotic events in adrenal chromaffin granules 
(Ali et al., 1989) and Weibel–Palade bodies of endothelial cells (Gerke et al., 2005). 
Interestingly, the complex has also been reported to bind and modulate the function of 
proteins and ion channels involved in nociception, such as TRPV4 (Ning et al., 2012) and 
Nav1.8 (Okuse et al., 2002). Our study identified AnxA2 as a direct interacting protein of 
TRPA1, as revealed by mass spectrometry-based screening and also from overexpression 
studies in a well-established heterologous expression system. HEK293T cells studies showed 
that p11 does not bind TRPA1 and that the AnxA2-TRPA1 interaction does not require a 
neuronal cell-specific mediator. These data, together with the fact that we did not detect 
p11 in proteomics results, suggest that AnxA2 might be interacting with TRPA1 in its 
homomeric form (without p11). This hypothesis is further supported by our identification of 
the AnxA2 domain involved in the interaction with TRPA1 in the first 15 residues of the 
AnxA2 protein; this region has indeed been demonstrated in previous studies to constitute  
the binding site of p11 (Kube et al., 1992) and suggests that TRPA1 and p11 could potentially 
even compete for binding AnxA2. Recently, a TRPA1 splice variant baptized TRPA1b has been 
described to interact and increase TRPA1 levels at the plasma membrane of sensory neurons 
(Zhou et al., 2013). Even though our data show that AnxA2 and TRPA1 physically interact 
independently of TRPA1b in a heterologous expression system, we cannot exclude the 
possibility that AnxA2 binds TRPA1b as well and regulates its function in sensory neurons. 
Currently available TRPA1 antibodies are in fact not suitable to differentiate among TRPA1 
isoforms and cannot help to address this question. This study identified and characterized a 
role of AnxA2 as an endogenous modulator of TRPA1 activity in nociceptive neurons in vitro 
and in vivo. The mechanisms underlying this regulation can be manifold. Our findings 
suggest that in sensory neurons the absence of AnxA2 translates in an increase of TRPA1 
plasma membrane expression and function in a subpopulation of nociceptive neurons, as 
indicated by immunohistochemistry, live labeling, electrophysiology and calcium imaging 
studies. Specifically, in AnxA2-/- neurons we observe enhancement of TRPA1-dependent 
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neuronal calcium responses and MO-gated currents, which correlate with an increase of 
TRPA1 channels at the surface of sensory neurons. As a confirmation that the observed 
phenotypes are due to the lack of AnxA2, its re-expression was able to counteract the 
increase in TRPA1 surface levels and neuronal sensitivity to the TRPA1 agonist MO measured 
in AnxA2-/- neurons. Previous studies demonstrated that the expression, activity and 
function of TRPA1 channels can be regulated by different signaling pathways involving 
inflammatory signals (Dai et al., 2007; Schmidt et al., 2009; Wang et al., 2008a), growth 
factors (Diogenes et al., 2007), microRNA (Park et al., 2014) and interaction with TRPV1 and 
the splice variant TRPA1b (Akopian et al., 2007; Staruschenko et al., 2010; Zhou et al., 2013). 
While mechanistically we demonstrated a clear role of AnxA2 in regulating TRPA1 plasma 
membrane expression, the potential contribution of AnxA2 to each of these processes 
remains to be investigated. Our in vivo studies showed that the enhanced TRPA1 plasma 
membrane expression in AnxA2-/- sensory neurons nicely correlates with enhanced TRPA1-
dependent pain behaviors in AnxA2-/-mice. These findings highlight the importance that 
controlling TRPA1 membrane availability might have for in vivo nociceptive signaling and are 
in accordance with previous studies (Obata et al., 2005; Schmidt et al., 2009; Zhou et al., 
2013). The results of our immunohistochemical experiments confirm early reports (Naciff et 
al., 1996), showing that AnxA2 is expressed in both TRPA1-positive and TRPA1-negative 
subpopulations of DRG neurons. Therefore it might modulate other proteins and signaling 
pathways in addition to TRPA1. In sensory neurons, TRPA1 is also usually coexpressed with 
the capsaicin receptor TRPV1, in small diameter peptidergic afferent fibers (Kobayashi et al., 
2005; Story et al., 2003). In fact, ablation of TRPV1 neurons with resiniferatoxin (a 
superpotent TRPV1 agonist) has been shown to induce loss of response to both capsaicin 
and mustard oil (Pecze et al., 2009), suggesting a high degree of colocalization of the two 
channels. This and other characteristics that make the two channels close relatives, led us to 
investigate the potential effect of AnxA2 on TRPV1 both in vitro and in vivo. Specifically we 
observed that: (1) from biochemical data in HEK293T cells AnxA2 does not physically bind to 
TRPV1; (2) cellular calcium responses to capsaicin were not altered in DRG cultures from 
AnxA2-/- mice compared to WT littermates; (3) in DRG cryosections the number of sensory 
neurons immunoreactive to TRPV1 was not changed; (4) mouse response to heat and 
nocifensive behaviors following intraplantar capsaicin injection were not different between 
genotypes. These results support a certain degree of specificity for the role of AnxA2 in 
regulating TRPA1-dependent nociception. Noteworthy, relevant evidence that nociceptive 
signaling is not generally perturbed in the absence of AnxA2 derives from the fact that 
baseline thermal and mechanical responses are not altered in AnxA2-/- mice. Moreover, the 
pain paradigms where we performed intraplantar injection of the specific agonist (MO or 
capsaicin) followed by assessment of nocifensive response require transmission via primary 
afferent nociceptors followed by supraspinal processing of the stimulus (Wang et al., 2013). 
Hence, the selective alteration of TRPA1-mediated behaviors argues against gross changes in 
supraspinal nociceptive signaling in AnxA2-/- mice. This is further supported by the fact that 
upon CFA-induced inflammatory pain, in these animals only specific hypersensitivity states 
(cold but not heat and mechanical allodynia) are affected. In conclusion, this study on the 
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characterization of AnxA2 as a novel TRPA1-interacting partner contributed to decipher the 
elusive composition of TRPA1-associated protein complexes. We demonstrated a role for 
AnxA2 as an endogenous modulator of TRPA1 activity in vitro and in vivo, and defined a 
mechanism capable of regulating TRPA1-mediated nociception in vertebrates. Furthermore, 
these results highlight the impact of protein-protein interactions in the modulation of TRPA1 
activity and nociceptive signaling. A crucial question that follows these conclusions relates to 
the possibility of dynamic changes of TRPA1 interactome in different conditions. In the next 




4.2 TRPA1 interactome undergoes dramatic changes during 
inflammatory pain 
 
The study on the identification and characterization of AnxA2 as a novel modulator of TRPA1 
function paved the way for a more thorough investigation of the dynamic changes of TRPA1-
associated protein complexes.  Considering the established contribution of TRPA1 to the 
modulation of inflammatory pain states (Bautista et al., 2006; da Costa et al., 2010; del 
Camino et al., 2010; Obata et al., 2005; Petrus et al., 2007; Zhou et al., 2013), and our results 
supporting TRPA1-involvement in CFA-induced allodynia (paragraph 3.1.8), we performed an 
interactomics screening of TRPA1-protein complexes in mice subjected to the CFA-model of 
inflammatory pain. In our hypothesis, TRPA1 interactome could undergo substantial changes 
between a physiological and a pathophysiological context, and also among different pain 
states. This would potentially translate in dramatic alterations of TRPA1 activity and 
sensitization, which, as already discussed, is known to contribute to nociceptor excitability 
and ultimately to hypersensitivity and altered pain perception (Basbaum et al., 2009; 
Patapoutian et al., 2009). A qualitative comparison of specifically identified proteins would 
give insights into pain-related channel protein complexes, and might even uncover novel 
targets for pain treatment. Furthermore, a relevant part of the changes associated to a 
targeted alteration of a biological system can be appreciated only with access to quantitative 
information. Here is where quantitative proteomics comes into play, dramatically raising the 
quality and depth of the obtained data. Until just about a decade ago, quantitative studies 
were limited to investigation of changes in gene expression mainly using oligonucleotide 
chips, in so-called transcriptomics studies (Ong and Mann, 2005). However, in this way only 
changes at the mRNA level can be assessed, and parallel analyses even using advanced 
technology have generally reported that, globally, transcriptome and proteome exhibit poor 
correlation (Bonaldi et al., 2008; Kumar and Mann, 2009).  
 
In fact, proteins form the executive machinery that carry out most cellular functions, usually 
via stable or transient association into protein complexes. To date many proteomics studies 
have been performed to elucidate the components of multiprotein complexes (the 
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interactome) for several ion channels and receptors. Relevant studies contributed to the 
identification of cornichons proteins as auxiliary subunits of AMPA-type glutamate 
receptors, which have been shown to affect channel gating and expression in the rat brain 
(Schwenk et al., 2009); another study characterized the composition of NMDAR multiprotein 
complexes in the mouse brain, and their role in synaptic plasticity and learning (Husi et al., 
2000). In a very recent and relevant study, Hanack and colleagues used a proteomics 
approach to identify components of TRPV1-associated protein complexes and thus 
uncovered a new role for the GABAB1 receptor subunit in the modulation of TRPV1 
sensitization. They generated transgenic mice expressing an affinity-tagged version of 
TRPV1, and then used sensory neurons from these animals for coimmunoprecipitation and 
mass spectrometry analysis (Hanack et al., 2015). While this strategy proved successful in 
the identification of the GABAB1 receptor subunit as a novel binding partner and modulator 
of TRPV1 activity, this represent a major difference respect to the approach we adopted. We 
decided to use sensory neurons from naïve animals as the biological basis for the 
interactomics screening in order to selectively target native TRPA1 channel; while this 
necessarily demands more tissue, in this way we were more likely to detect real and 
biologically relevant interactions, respect to a system where the bait is overexpressed and, 
therefore, very likely not in physiological amounts. This factor might have a significant 
impact in the incidence of false positive identifications, which is likely to be less with our 
approach. Moreover, the absence of any exogenous affinity tag would further support this 
hypothesis. Several proteomics profiling studies advocate that gene expression and protein 
composition can undergo fundamental reorganization from physiological to pathological 
conditions (Huang et al., 2008; Melemedjian et al., 2013; Vacca et al., 2014; Zou et al., 2012) 
Nevertheless, to date only very few studies compared ion channel-multiprotein complexes 
between physiological and pathological conditions (Tu et al., 2010; Van den Oever et al., 
2008). Our mass spectrometry-based proteomics approach revealed the interactome of 
TRPA1 channels in the context of inflammatory pain induced by CFA. The large datasets 
generated by quantitative proteomics can be difficult to interpret and we performed 
extensive data analysis in order to get relevant information. Upon application of selective 
criteria and analysis of the raw data coming from each single biological replicate, we 
determined high-confidence TRPA1-binding partners specific for either condition (VEH and 
CFA), and measured very limited overlap between them (Fig.13A). We realized volcano plots 
and tested different variations thereof to visualize the results, finding positive as well as 
negative characteristics in the way the data were represented. While there is not a perfect 
way to analyze and display data like these, we can gather information from them all and use 
it in combination for the best possible selection of high priority candidates for follow-up and 
validation. For example, we could prioritize candidates already selected according to our 
criteria in first analysis, and which on top show a significant p-value, as the ones identified by 
red spots in the volcano plot (Fig.15). Very importantly, the changes we observed by mass-
spectrometry are now in the process of being validated with different orthogonal methods, 
among which are western blotting, immunostainings and proximity ligation assays (PLA). The 
gene ontology (GO) analysis indicate that an important fraction of the proteins interacting 
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with TRPA specifically during inflammatory pain is involved in protein transport and 
localization (Fig.13B). This is in line with a potential role in the trafficking of TRPA1 channels 
that can in turn determine its turnover, plasma membrane expression and function. 
Interestingly, we and others (Schmidt et al., 2009; Zhou et al., 2013) have already 
demonstrated a correlation between TRPA1 expression at the cell surface with nociceptor 
response and TRPA1-mediated nocifensive behavior in vivo (see chapter 3.1). The STRING 
association networks analysis allows the visualization of known and predicted interactions 
among proteins of the same database. On the one hand this information can help identifying 
potential pathways and cellular processes that are affected or modulated in the specific 
conditions. On the other hand it could also reflect an indirect association of some of these 
candidates to the bait. In fact, some proteins could interact and form complexes where only 
one member displays association to TRPA1, but upon coimmunoprecipitation they would be 
pulled-down together. While this indirect interaction could still be relevant and regulate 
TRPA1 function, it is unlikely that it could be reproduced for instance in a heterologous 
expression system where the intermediate link would be missing. These considerations, 
together with those described above and extensive literature search will drive orthogonal 
validation and the selection of the most interesting candidates for follow-up and 
investigation of the biological relevance of the interaction for nociceptive transmission.  
While this interactomics screening was performed at the peak of CFA-induced 
hypersensitivity for the mice (as measured by dynamic plantar aesthesiometer), we can 
speculate that the network of TRPA1-protein interactions might undergo significant changes 
over the course of the paradigm, especially once pain and hypersensitivity subside. The 
analysis of such dynamics might contribute to reveal mechanisms involved in the de-
sensitization of TRPA1 and would be focus of further investigation. One more point that 
needs to be underlined is the fact that our study is based on the use of sole male mice for 
the pain paradigm. This choice was justified by the widely held notion that the reproductive 
cycle renders females intrinsically more variable than males, and that employing same 
gender animals would avoid undesired additional variability. However, several reports are 
raising awareness about the need of considering both sexes in animal studies, which is 
relevant also in the pain field. For example, a recent study showed that mechanical pain 
hypersensitivity is mediated by different immune cells in male and female mice (Sorge et al., 
2015), and even proteomics studies reported sex-related differences during neuropathic 
pain (Vacca et al., 2014). While studies of both sexes necessarily result in additional 
expenses and workload, this issue had to be pointed out and will be considered for future 
studies. Nevertheless, our work significantly contributes to our understanding of TRPA1-
associated protein complexes and future studies will reveal the contribution of selected 







4.2.1 Potential relevance of these findings  
Numerous reports have established that the activity and function of receptors and ion 
channels are crucially modulated by their association into protein complexes. Our study 
contributed to show that protein complexes can be dynamic and occur specifically under 
certain conditions. The identification and characterization of such protein complexes 
characterizing the specific (patho-)physiological state can provide relevant information 
about channel function, and moreover contribute to the development of novel therapeutic 
strategies. As already discussed, direct targeting of primary noxious stimuli detectors 
seemed to provide only limited benefits, due to related side-effects. One example is direct 
TRPV1 antagonism, which correlated to hyperthermia and impaired noxious pain sensation, 
which critically increases the susceptibility to injury (Brederson et al., 2013). Targeting 
specific channel-protein interactions holds therefore the possibility for a better-targeted 
intervention.  
 
In a strategy ultimately aimed at quelling pain, the modulation of protein complexes to alter 
ion channel activity can be approached in different ways, which relates to the nature of the 
interaction. Some proteins have in fact been reported to enhance the activity of a pro-
nociceptive ion channel. In such a case, either the removal of the binding partner or the 
“uncoupling” of the interaction are desirable, which would lead to decreased pain behavior. 
On the other hand, protein complexes might contribute to limit channel activity, as we 
showed to be the case for AnxA2. In this case, the strategy would be to ameliorate the 
interaction, increasing the affinity or the number of binding partners (Rouwette et al., 2015). 
The identification of pain state-specific channel-protein complexes will give valuable insights 
into the molecular mechanisms of these conditions; furthermore, such knowledge could be 
exploited to selectively interfere with altered ion channel activity during pathological pain 
states, while preserving the physiological protective ability to detect noxious stimuli. This 
study and future ones regarding dynamic changes of TRPA1-associated proteins in different 
pain states could therefore open the possibility to develop targeted therapeutics for TRPA1-




4.3 NIPSNAP1 and Nocistatin modulate TRPA1 channels 
In a parallel line of research we focused our attention on a protein called 4-
Nitrophenylphosphatase domain and non-neuronal SNAP25-like protein homolog 1 
(NIPSNAP1), which showed an interesting expression profile in mouse DRG neurons.  In this 
line we performed a series of in vitro experiments aimed to investigate a potential role of 
NIPSNAP1 in TRPA1 regulation. Our results suggest that NIPSNAP1 is a protein expressed in 
nociceptors of DRGs where it possibly regulates the membrane expression and/or activity of 
TRPA1. In an attempt to further characterize this functional association, we investigated also 
the role of Nocistatin, a recently uncovered NIPSNAP1-binding partner and well known pain-
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modulator (Okuda-Ashitaka et al., 2012), for TRPA1-mediated nociception. This work 
revealed that both proteins have the potential to affect TRPA1 activity, while the 
characterization of the specific underlying mechanisms will be focus of further investigation. 
NIPSNAP1 belongs to the largely uncharacterized NIPSNAP family of proteins which 
comprises three additional members: NIPSNAP2, NIPSNAP3 and NIPSNAP4 (Okuda-Ashitaka 
et al., 2012). The peculiar nomenclature derives from the fact that some portions of the 
proteins structure resemble a 4-nitrophenylphosphatase domain and non-neuronal SNAP25-
like protein (Seroussi et al., 1998). The physiological functions of the NIPSNAP family remain 
elusive, even though the distinct genetic location of NIPSNAP1 sequence suggests a potential 
involvement in vesicular transport (Seroussi et al., 1998). NIPSNAP1 showed predominant 
expression in the brain, spinal cord, liver, and kidney (Okuda-Ashitaka et al., 2012). In the 
brain, it is especially enriched in synaptic membranes, cell surface and mitochondria of 
neuronal cells, but not glia. (Nautiyal et al., 2010). Over the past few years, NIPSNAP1 has 
been associated to a number of metabolic and nervous system pathologies. For instance, it 
has been reported to bind the amyloid precursor protein that is implicated in Alzheimer 
disease (Tummala et al., 2010), and NIPSNAP1 levels are increased during generalized 
seizures induced by kainate (Satoh et al., 2002). Despite the handful of studies on NIPSNAP 
proteins and their potential roles, there is recent evidence indicating that NIPSNAP1 
associates with TRPV6 channels in mouse liver cells, which results in a dramatic inhibition of 
the channel function, with currents virtually abolished (Schoeber et al., 2008). NIPSNAP2, 
another member of the NIPSNAP family has instead been shown to modulate L-type Ca(2+) 
channels, and downstream CREB (cAMP response element-binding protein) signaling, in a 
neuronal cell line (Brittain et al., 2012). These studies potentially suggest a role for the 
proteins of the NIPSNAP family in the regulation of ion channels. Although NIPSNAP1 
expression has already been described in different brain regions (Nautiyal et al., 2010), no 
report had previously reported of its distribution in the peripheral nervous system. Our 
immunohistochemical studies established that NIPSNAP1 is abundantly expressed in sensory 
neurons of mouse DRGs and furthermore demonstrate enrichment in a nociceptive 
subpopulation coexpressing the marker Peripherin. This expression pattern potentially 
suggests a still-unknown role of NIPSNAP1 in a subset of mouse nociceptors which is likely to 
match, at least to a certain extent, the subset which expresses TRPA1. We therefore aimed 
at investigating a potential role of NIPSNAP1 in TRPA1 regulation, by testing the outcomes of 
NIPSNAP1 modulation in vitro in sensory neuron cultures. Concerned by potential 
compensatory mechanisms that would possibly mask a phenotype following selective 
NIPSNAP1 knock-down, we aimed at overexpressing the protein in DRG cultures. 
Interestingly, immunostainings revealed a decrease in the number of TRPA1-immunoreactive 
neurons upon NIPSNAP1 overexpression, suggesting a potential intriguing role of NIPSNAP1 
in modulating TRPA1 expression in sensory neurons. We then proposed that these changes 
could be reflected by TRPA1-mediated cellular calcium responses, which directly reflect the 
number and activity of TRPA1 channels expressed at the plasma membrane. If the 
modulation of TRPA1 by NIPSNAP1 is modest, the high heterogenity of sensory neuron 
populations in DRG cultures would complicate the identification of a possible phenotype. 
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Therefore we translated these findings to a heterologous expression system (HEK293T cells) 
where we could maintain better control over the cellular environment and more easily 
manipulate NIPSNAP1 expression. In agreement with DRG data, we measured lower number 
of TRPA1-positive cells upon NIPSNAP1 overexpression. We then correlated the decresed 
TRPA1-immunoreactivity measured upon NIPSNAP1 overexpression with a reduction of 
neuronal response to specific TRPA activation. Noteworthy, the total number of TRPA1-
expressing cells did not show any difference between conditions. As already mentioned, the 
TRPA1 antibody used has been reported to preferentially label cells with relatively high 
expression of TRPA1 (Schmidt et al., 2009); this therefore suggests that the observed 
difference is related to this subpopulation of TRPA1-expressing cells. This phenotype could 
be explained by an action of NISPNAP1 at different levels, ultimately affecting TRPA1 
expression and function. Hypothetically, NIPSNAP1 could directly interact with TRPA1, 
targeting the channel for degradation. This process may in turn require one or more 
accessory proteins, acting as an intermediate link. Alternatively, NIPSNAP1 could be affecting 
other cellular pathways, possibly even at pre-translational level, which would ultimately 
result in a decreased TRPA1 expression. In an attempt to address some of these questions 
and evaluate a potential direct interaction between NIPSNAP1 and TRPA1, we performed 
coimmunoprecipitation experiments in HEK293T cells transfected with both proteins. 
Unfortunately, preliminary results from these efforts (data not shown, experiments 
performed by Oli Abate Fulas and Julia Sondermann) are inconclusive and do not allow us 
clear statements about the molecular relation between the two proteins. At the same time, 
NIPSNAP1 could also be directly inhibiting TRPA1 activity, mechanism that has already been 
suggested for its modulating action on TRPV6 channels (Schoeber et al., 2008).   
 
An intriguing recent study has shed some lights on a novel potential role of NIPSNAP1 in pain 
transmission by uncovering its interaction with Nocistatin, a neuropeptide that is produced 
from the same precursor protein as Nociceptin/orphanin FQ (N/OFQ) (Okuda-Ashitaka et al., 
2012). Nocistatin is well known to be involved in nociceptive signaling: in vivo it counteracts 
N/OFQ-induced allodynia and hyperalgesia, and directly modulates inflammatory pain 
responses in a dose-dependent manner (Nakano et al., 2000; Okuda-Ashitaka et al., 1998; 
Okuda-Ashitaka et al., 2012; Zeilhofer et al., 2000). The study from Okuda-Ashitaka and 
colleagues reported the interaction between Nocistatin and NIPSNAP1 and described that 
the inhibition of Nociceptin-induced allodynia by Nocistatin measured in WT mice was 
completely lacking in NIPSNAP1-deficient animals (Okuda-Ashitaka et al., 2012). In the light 
of these findings, we attempted to further investigate the functional association between 
NIPSNAP1 and TRPA1 by examining Nocistatin. Interestingly, calcium imaging experiments 
revealed that stimulation with Nocistatin significantly enhances TRPA1-mediated calcium 
responses in sensory neuron cultures. These results are in line with previous reports showing 
a pro-nociceptive effect of Nocistatin, which facilitates nociceptive flexor reflexes (Xu et al., 
1999) and enhances nocifensive behavior in the rat formalin test (Zeilhofer et al., 2000). A 
study from Inoue and colleagues suggested that part of these effects is mediated by 
neurotransmitter release from a population of capsaicin-sensitive (and therefore TRPV1-
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expressing) neurons (Inoue et al., 2003). Interestingly, a subset of these neurons is also 
bound to express TRPA1 as the two channels are known to be largely coexpressed (Pecze et 
al., 2009; Story et al., 2003). Despite almost a decade has passed and extensive literature 
accumulated about Nocistatin and its role in pain, the specific molecular mechanisms and 
target(s) of its action are still elusive (Okuda-Ashitaka and Ito, 2015). These considerations, 
together with the fact that cellular responses to TRPV1 activation by capsaicin were not 
affected, led us to hypothesize a potential involvement of TRPA1 as one of the target 
receptors through which Nocistatin modulates pain transmission. Our data showed that MO-
gated neuronal calcium responses are enhanced by Nocistatin. Mechanistically, this effect 
did not seem to be mediated by alteration of the plasma membrane expression of the 
channel, as showed by live labeling of surface TRPA1. While we cannot exclude a different 
phenotype at higher concentrations, Nocistatin did not induce cellular calcium influx on its 
own (data not shown), and therefore it is likely not gating TRPA1 directly. It is possible that 
Nocistatin’s effect is mediated by an enhancement of TRPA1 activity at the cell surface: this 
could be the result of either direct action on the channel (as an allosteric modulator) or in 
turn mediated by alteration of other intracellular signaling pathways that regulate TRPA1 
activity (Lapointe and Altier, 2011). Whether biophysical properties of the channel are 
modulated by treatment with Nocistatin will be focus of further investigation. In this context 
we also hypothesized that Nocistatin-induced enhancement of cellular responses to MO 
might require NIPSNAP1, as this is known to be the case for the inhibition of Nociceptin-
induced allodynia exerted by Nocistatin (Okuda-Ashitaka et al., 2012). However, calcium 
imaging studies upon NIPSNAP1 knock-down showed a trend that reflects what observed in 
WT cultures treated with Nocistatin, suggesting that NIPSNAP1 is dispensable for the 
observed phenotype.  
 
In conclusion we uncovered a potential role for both NIPSNAP1 and Nocistatin as 
endogenous modulators of TRPA1 activity in vitro in sensory neurons. While our studies 
suggest that NIPSNAP1 and Nocistatin act independently to affect TRPA1 activity, future 
studies will contribute to characterize the underlying mechanisms and also the potential 
















The transient receptor potential A1 (TRPA1) channel is essential for vertebrate pain. TRPA1 
plays a fundamental role as a primary detector of noxious stimuli of physical and chemical 
nature, and is critically involved in different pain states. Even though TRPA1 activation 
modalities have been studied extensively, the network of protein interactions regulating 
TRPA1 (the so-called TRPA1 interactome) is only poorly understood. Considering the crucial 
role of TRPA1 in pain signaling, it is mandatory to shed light on the elusive molecular 
machinery regulating TRPA1 channels in sensory neurons. This project was therefore aimed 
at getting insights into the mechanisms of TRPA1 regulation by identifying TRPA1-protein 
complexes and characterizing their biological meaning in the context of nociception.   
 
A mass spectrometry-based proteomics approach led to the discovery of the physical 
association of Annexin A2 (AnxA2) with native TRPA1 in mouse sensory neurons. AnxA2 is 
enriched in a subpopulation of sensory neurons and coexpressed with TRPA1. Furthermore, 
we observed an increase of TRPA1 membrane levels in cultured sensory neurons from 
AnxA2-deficient mice. Functional studies suggest that AnxA2 limits the availability and 
consequently the activity of TRPA1 channels at the plasma membrane of sensory neurons. 
Moreover, our in vitro observations were reflected in enhanced nocifensive responses of 
AnxA2 knock-out mice specifically upon TRPA1 activation in vivo. TRPA1 channels have been 
shown to contribute to hypersensitivity to cold stimuli during inflammation. We therefore 
investigated the possible impact of AnxA2 on TRPA1 function also in this context employing 
the well-established complete Freund´s adjuvant (CFA) model of persistent inflammation in 
mice. AnxA2-deficient mice showed enhanced hypersensitivity on a cold plate upon CFA 
injection, whereas the hypersensitivity to heat and mechanical stimulation were not 
affected. In conclusion, we characterized AnxA2 as a novel TRPA1-associated protein which 
specifically regulates TRPA1 channels in vitro and in vivo.  
 
These findings pave the way for a more thorough investigation of the dynamic changes in 
TRPA1-associated protein complexes in different conditions. In this context we submitted 
mice to the established Complete Freund’s Adjuvant (CFA)-model of inflammatory pain and 
isolated TRPA1-protein complexes from sensory neurons. Samples were submitted to state-
of-the-art quantitative mass spectrometry analysis to compare complexes between CFA and 
control mice and therefore identify dynamic changes in TRPA1 interactome. This work 
revealed a dramatic alteration of TRPA1-associated protein complexes in the context of 
inflammatory pain, and the functional characterization of selected candidates that will 
follow this study might uncover new players in the development and maintenance of 
inflammatory pain. 
 
In a separate set of experiments we focused our attention on a protein called 4-
Nitrophenylphosphatase domain and non-neuronal SNAP25-like protein homolog 1 
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(NIPSNAP1), which function is largely still unknown. NIPSNAP1 showed to be expressed in 
nociceptive neurons of mouse dorsal root ganglia and functional studies suggested that it 
can modulate TRPA1 expression and/or function upon overexpression. A role of NIPSNAP1 in 
nociceptive transmission has been recently uncovered by the identification of its physical 
association with Nocistatin, a neuropeptide involved in pain signaling. In this context we 
investigated Nocistatin and found that it enhances TRPA1-mediated cellular calcium 
responses in DRG neurons. Mechanistically, this effect does not seem to be mediated by a 
modulation of TRPA1 plasma membrane expression, and NIPSNAP1 knock-down did not 
affect it. Future studies will contribute to characterize the underlying mechanisms and also 
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Appendix. List of proteins identified in the interactomics screening for TRPA1-protein 
complexes in inflammatory pain according to the Venn diagram and the criteria shown in 
figure 13A. 
 






Ras-related protein Rab-7a OS=Mus musculus GN=Rab7a PE=1 
SV=2 
Rab7a P51150 
AP-2 complex subunit alpha-1 OS=Mus musculus GN=Ap2a1 
PE=1 SV=1 
Ap2a1 P17426 
Protein transport protein Sec31A OS=Mus musculus GN=Sec31a 
PE=1 SV=2 
Sec31a Q3UPL0 
Dual specificity protein phosphatase 15 OS=Mus musculus 
GN=Dusp15 PE=2 SV=3 
Dusp15 Q8R4V2 
ATP synthase subunit f, mitochondrial OS=Mus musculus 
GN=Atp5j2 PE=1 SV=3 
Atp5j2 P56135 
Serine/arginine-rich splicing factor 2 OS=Mus musculus GN=Srsf2 
PE=1 SV=4 
Srsf2 Q62093 
Myelin P2 protein OS=Mus musculus GN=Pmp2 PE=2 SV=2 Pmp2 P24526 
Rho-related GTP-binding protein RhoG OS=Mus musculus 
GN=Rhog PE=2 SV=1 
Rhog P84096 
AP-2 complex subunit sigma OS=Mus musculus GN=Ap2s1 PE=1 
SV=1 
Ap2s1 P62743 
F-actin-capping protein subunit beta OS=Mus musculus 
GN=Capzb PE=1 SV=3 
Capzb P47757 
Alpha-actinin-1 OS=Mus musculus GN=Actn1 PE=1 SV=1 Actn1 Q7TPR4 
40S ribosomal protein S25 OS=Mus musculus GN=Rps25 PE=1 
SV=1 
Rps25 P62852 
60S acidic ribosomal protein P1 OS=Mus musculus GN=Rplp1 
PE=2 SV=1 
Rplp1 P47955 
Tropomyosin beta chain OS=Mus musculus GN=Tpm2 PE=1 SV=1 Tpm2 P58774 
Unconventional myosin-If OS=Mus musculus GN=Myo1f PE=1 
SV=1 
Myo1f P70248 
Histone H1.5 OS=Mus musculus GN=Hist1h1b PE=1 SV=2 Hist1h1b P43276 
60S ribosomal protein L36a OS=Mus musculus GN=Rpl36a PE=1 
SV=2 
Rpl36a P83882 
Myosin light chain 6B OS=Mus musculus GN=Myl6b PE=2 SV=1 Myl6b Q8CI43 





ATP synthase subunit delta, mitochondrial OS=Mus musculus 
GN=Atp5d PE=1 SV=1 
Atp5d Q9D3D9 
60S ribosomal protein L38 OS=Mus musculus GN=Rpl38 PE=2 
SV=3 
Rpl38 Q9JJI8 
Ferritin light chain 1 OS=Mus musculus GN=Ftl1 PE=1 SV=2 Ftl1 P29391 
Ubiquitin-associated protein 2-like OS=Mus musculus 
GN=Ubap2l PE=1 SV=1 
Ubap2l Q80X50 
60S ribosomal protein L35a OS=Mus musculus GN=Rpl35a PE=1 
SV=2 
Rpl35a O55142 
Syntenin-1 OS=Mus musculus GN=Sdcbp PE=1 SV=1 Sdcbp O08992 
60S ribosomal protein L13 OS=Mus musculus GN=Rpl13 PE=2 
SV=3 
Rpl13 P47963 
Epidermal growth factor receptor substrate 15 OS=Mus 
musculus GN=Eps15 PE=1 SV=1 
Eps15 P42567 
Collagen alpha-1(XIV) chain OS=Mus musculus GN=Col14a1 PE=2 
SV=2 
Col14a1 Q80X19 
Glutathione S-transferase Mu 1 OS=Mus musculus GN=Gstm1 
PE=1 SV=2 
Gstm1 P10649 
Apolipoprotein O OS=Mus musculus GN=Apoo PE=2 SV=1 Apoo Q9DCZ4 











Inosine-5'-monophosphate dehydrogenase 1 OS=Mus musculus 
GN=Impdh1 PE=2 SV=2 
Impdh1 P50096 
Kinesin-like protein KIF3A OS=Mus musculus GN=Kif3a PE=1 
SV=2 
Kif3a P28741 
Ubiquitin-like modifier-activating enzyme 1 OS=Mus musculus 
GN=Uba1 PE=1 SV=1 
Uba1 Q02053 
Leucine-rich repeat flightless-interacting protein 1 OS=Mus 
musculus GN=Lrrfip1 PE=1 SV=2 
Lrrfip1 Q3UZ39 
1-acyl-sn-glycerol-3-phosphate acyltransferase epsilon OS=Mus 
musculus GN=Agpat5 PE=2 SV=2 
Agpat5 Q9D1E8 
PRA1 family protein 3 OS=Mus musculus GN=Arl6ip5 PE=1 SV=2 Arl6ip5 Q8R5J9 
Nucleosome assembly protein 1-like 4 OS=Mus musculus 
GN=Nap1l4 PE=1 SV=1 
Nap1l4 Q78ZA7 
Serine/arginine-rich splicing factor 10 OS=Mus musculus Srsf10 Q9R0U0 
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GN=Srsf10 PE=1 SV=2 
Serpin H1 OS=Mus musculus GN=Serpinh1 PE=1 SV=3 Serpinh1 P19324 
Eukaryotic initiation factor 4A-III OS=Mus musculus GN=Eif4a3 
PE=2 SV=3 
Eif4a3 Q91VC3 
Eukaryotic translation initiation factor 2 subunit 3, X-linked 
OS=Mus musculus GN=Eif2s3x PE=1 SV=2 
Eif2s3x Q9Z0N1 
RNA-binding protein 39 OS=Mus musculus GN=Rbm39 PE=1 
SV=2 
Rbm39 Q8VH51 
ATPase Asna1 OS=Mus musculus GN=Asna1 PE=1 SV=2 Asna1 O54984 
Ras GTPase-activating protein-binding protein 1 OS=Mus 
musculus GN=G3bp1 PE=1 SV=1 
G3bp1 P97855 
Junctional adhesion molecule C OS=Mus musculus GN=Jam3 
PE=1 SV=2 
Jam3 Q9D8B7 
Plastin-2 OS=Mus musculus GN=Lcp1 PE=1 SV=4 Lcp1 Q61233 
40S ribosomal protein S17 OS=Mus musculus GN=Rps17 PE=1 
SV=2 
Rps17 P63276 
Clathrin interactor 1 OS=Mus musculus GN=Clint1 PE=1 SV=2 Clint1 Q99KN9 
Ras-related protein Rap-1b OS=Mus musculus GN=Rap1b PE=2 
SV=2 
Rap1b Q99JI6 
Dedicator of cytokinesis protein 7 OS=Mus musculus GN=Dock7 
PE=1 SV=3 
Dock7 Q8R1A4 
Syntaxin-8 OS=Mus musculus GN=Stx8 PE=1 SV=1 Stx8 O88983 
BAG family molecular chaperone regulator 2 OS=Mus musculus 
GN=Bag2 PE=1 SV=1 
Bag2 Q91YN9 
Myosin light chain 3 OS=Mus musculus GN=Myl3 PE=1 SV=4 Myl3 P09542 











Ras-related protein Rab-8B OS=Mus musculus GN=Rab8b PE=1 
SV=1 
Rab8b P61028 
39S ribosomal protein L11, mitochondrial OS=Mus musculus 
GN=Mrpl11 PE=2 SV=1 
Mrpl11 Q9CQF0 
Serine/threonine-protein phosphatase PGAM5, mitochondrial 
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